Medtronic (MDT) 10-Q 9 Dec 15 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Oct. 30, 2015	Dec. 03, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Medtronic plc
Entity Central Index Key	1,613,103
Document Period End Date	Oct. 30, 2015
Current Fiscal Year End Date	--04-29
Document Type	10-Q
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Ordinary Shares Outstanding		1,406,155,722
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Income Statement [Abstract]
Net sales	$ 7,058	$ 4,366	$ 14,332	$ 8,639
Costs and expenses:
Cost of products sold	2,182	1,142	4,638	2,247
Research and development expense	545	374	1,103	739
Selling, general, and administrative expense	2,343	1,507	4,792	3,013
Special charges	0	100	0	100
Restructuring charges, net	73	0	140	30
Certain litigation charges	26	0	26	0
Acquisition-related items	49	61	120	102
Amortization of intangible assets	483	89	964	176
Other expense, net	57	63	118	114
Operating profit	1,300	1,030	2,431	2,118
Interest income	(107)	(86)	(222)	(178)
Interest expense	324	94	630	191
Interest expense, net	217	8	408	13
Income from operations before income taxes	1,083	1,022	2,023	2,105
Provision for income taxes	563	194	683	406
Net income	$ 520	$ 828	$ 1,340	$ 1,699
Basic earnings per share (usd per share)	$ 0.37	$ 0.84	$ 0.95	$ 1.72
Diluted earnings per share (usd per share)	$ 0.36	$ 0.83	$ 0.94	$ 1.70
Basic weighted average shares outstanding (shares)	1,412.9	981.9	1,415.6	987.5
Diluted weighted average shares outstanding (shares)	1,428.8	993	1,432.7	999.4
Cash dividends declared per ordinary share (usd per share)	$ 0.380	$ 0.305	$ 0.760	$ 0.610

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 520	$ 828	$ 1,340	$ 1,699
Other comprehensive (loss) income, net of tax:
Unrealized (loss) gain on available-for-sale securities, net of tax (benefit) expense of $(41), $(19), $(115), and $13, respectively	(76)	(34)	(207)	20
Translation adjustment	(33)	(130)	(59)	(129)
Net change in retirement obligations, net of tax expense of $10, $6, $20, and $12, respectively	22	25	35	42
Unrealized (loss) gain on derivatives, net of tax (benefit) expense of $(13), $68, $(33), and $89, respectively	(28)	121	(56)	158
Other comprehensive (loss) income	(115)	(18)	(287)	91
Comprehensive income	$ 405	$ 810	$ 1,053	$ 1,790

Condensed Consolidated Stateme4

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Other Comprehensive Income (Loss), Tax
Unrealized (loss) gain on investments, tax (benefit) expense	$ (41)	$ (19)	$ (115)	$ 13
Net change in retirement obligations, tax expense	10	6	20	12
Unrealized (loss) gain on derivatives, tax (benefit) expense	$ (13)	$ 68	$ (33)	$ 89

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Current assets:
Cash and cash equivalents	$ 2,378	$ 4,843
Investments	14,851	14,637
Accounts receivable, less allowances of $158 and $144, respectively	5,044	5,112
Inventories	3,516	3,463
Tax assets	1,619	1,335
Prepaid expenses and other current assets	1,315	1,454
Total current assets	28,723	30,844
Property, plant, and equipment	9,215	8,863
Accumulated depreciation	(4,537)	(4,164)
Property, plant, and equipment, net	4,678	4,699
Goodwill	41,274	40,530
Other intangible assets, net	27,731	28,101
Long-term tax assets	825	774
Other assets	1,714	1,737
Total assets	104,945	106,685
Current liabilities:
Short-term borrowings	2,158	2,434
Accounts payable	1,447	1,610
Accrued compensation	1,389	1,611
Accrued income taxes	533	935
Deferred tax liabilities	142	119
Other accrued expenses	2,457	2,464
Total current liabilities	8,126	9,173
Long-term debt	33,690	33,752
Long-term accrued compensation and retirement benefits	1,577	1,535
Long-term accrued income taxes	2,771	2,476
Long-term deferred tax liabilities	4,766	4,700
Other long-term liabilities	1,746	1,819
Total liabilities	$ 52,676	$ 53,455
Commitments and contingencies (Notes 3 and 16)
Shareholders’ equity:
Ordinary shares— par value $0.0001	$ 0	$ 0
Retained earnings	53,740	54,414
Accumulated other comprehensive loss	(1,471)	(1,184)
Total shareholders’ equity	52,269	53,230
Total liabilities and shareholders’ equity	$ 104,945	$ 106,685

Condensed Consolidated Balance6

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 158	$ 144
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014
Operating Activities:
Net income	$ 1,340	$ 1,699
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,397	423
Acquisition-related items	222	6
Provision for doubtful accounts	30	17
Deferred income taxes	(274)	(61)
Stock-based compensation	209	82
Other, net	(70)	(8)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	(1)	(64)
Inventories	(326)	(170)
Accounts payable and accrued liabilities	(369)	26
Other operating assets and liabilities	73	73
Certain litigation charges	26	0
Certain litigation payments	(162)	(800)
Net cash provided by operating activities	2,095	1,223
Investing Activities:
Acquisitions, net of cash acquired	(997)	(578)
Additions to property, plant, and equipment	(446)	(210)
Purchases of marketable securities	(3,370)	(3,024)
Sales and maturities of marketable securities	2,752	2,665
Other investing activities, net	(13)	(6)
Net cash used in investing activities	(2,074)	(1,153)
Financing Activities:
Acquisition-related contingent consideration	(19)	(5)
Change in short-term borrowings, net	1,277	1,611
Proceeds from short-term borrowings (maturities greater than 90 days)	48	150
Payments on long-term debt	(1,608)	(7)
Dividends to shareholders	(1,075)	(602)
Issuance of ordinary shares	263	312
Repurchase of ordinary shares	(1,460)	(1,620)
Other financing activities, net	49	34
Net cash used in financing activities	(2,525)	(127)
Effect of exchange rate changes on cash and cash equivalents	39	(59)
Net change in cash and cash equivalents	(2,465)	(116)
Cash and cash equivalents at beginning of period	4,843	1,403
Cash and cash equivalents at end of period	2,378	1,287
Supplemental Cash Flow Information
Cash paid for income taxes	1,021	357
Cash paid for interest	$ 652	$ 250

Basis of Presentation

Basis of Presentation	6 Months Ended
	Oct. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Medtronic plc is the successor registrant to Medtronic, Inc. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended April 24, 2015 . The Company’s fiscal years 2016 , 2015 , and 2014 will end or ended on April 29, 2016 , April 24, 2015 , and April 25, 2014 , respectively. Fiscal year 2016 is a 53-week year, and the extra week occurred during the first quarter.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Oct. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In April 2014, the Financial Accounting Standards Board (FASB) issued amended guidance for reporting discontinued operations. The amended guidance changes the criteria for determining when the results of operations are to be reported as discontinued operations and expands the related disclosure requirements. The guidance defines a discontinued operation as a component or group of components that is disposed of or classified as held for sale, which is a strategic shift that has, or will have, a major effect on financial position and results of operations. The Company prospectively adopted this accounting guidance in the first quarter of fiscal year 2016. Its adoption did not have a material impact on the Company's condensed consolidated financial statements. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s condensed consolidated financial statements.

Acquisitions and Acquisition-Re

Acquisitions and Acquisition-Related Items	6 Months Ended
	Oct. 30, 2015
Business Combinations [Abstract]
Acquisitions and Acquisition-Related Items	Acquisitions and Acquisition-Related Items The Company had various acquisitions and other acquisition-related activity during the first two quarters of fiscal years 2016 and 2015 . Certain acquisitions were accounted for as business combinations as noted below. In accordance with authoritative guidance on business combination accounting, the assets and liabilities of the companies acquired were recorded and consolidated as of the acquisition date at their respective fair values. Unless otherwise disclosed, the pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three and six months ended October 30, 2015 or October 24, 2014 . The results of operations related to each company acquired have been included in the Company's condensed consolidated statements of income since the date each company was acquired. Acquisition of Covidien public limited company On January 26, 2015 (Acquisition Date), pursuant to the transaction agreement, dated as of June 15, 2014 (the Transaction Agreement), the Company acquired Covidien plc (Covidien), and Covidien and Medtronic, Inc. became subsidiaries of Medtronic (collectively, the Transactions). In connection with the consummation of the Transactions, Medtronic re-registered as a public limited company organized under the laws of Ireland. On January 26, 2015, (a) each Covidien ordinary share was converted into the right to receive $35.19 in cash and 0.956 of a newly issued Medtronic plc ordinary share (the Arrangement Consideration) in exchange for each Covidien share held by such shareholders, and (b) each share of Medtronic, Inc. common stock was converted into the right to receive one Medtronic plc ordinary share. Total consideration was approximately $50 billion , consisting of $16 billion cash and $34 billion of non-cash consideration. Based on the number of outstanding shares of Medtronic, Inc. and Covidien as of January 23, 2015 (the last business day prior to the close of the transaction), former Medtronic, Inc. and Covidien shareholders held approximately 69 percent and 31 percent , respectively, of the Company's ordinary shares after giving effect to the acquisition. Covidien is a global leader in the development, manufacture, and sale of healthcare products for use in clinical and home settings. The operating results for Covidien are included in the Minimally Invasive Therapies Group, Cardiac and Vascular Group, and Restorative Therapies Group segments. Fair Value of Assets Acquired and Liabilities Assumed The Company accounted for the acquisition of Covidien as a business combination using the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the Acquisition Date. Based upon a preliminary acquisition valuation, the Company acquired $18.3 billion of customer-related intangible assets, $7.0 billion of technology-based intangible assets, $0.4 billion of tradenames, with weighted average estimated useful lives of 18 , 16 , and 6 years, respectively, $0.4 billion of in-process research and development (IPR&D), and $29.6 billion of goodwill. During the six months ended October 30, 2015 , the Company made opening balance sheet adjustments to update estimates primarily related to other current assets, intangible assets, goodwill, certain property values, other current liabilities, and the related deferred tax impacts. The largest opening balance sheet adjustment related to a $121 million receivable as a result of the settlement reached with C.R. Bard, Inc. (Bard) related to the Company's pelvic mesh litigation. For additional information on the Company's pelvic mesh litigation, see Note 16 to the condensed consolidated financial statements . The fair value of assets acquired and liabilities assumed continues to be evaluated. Management is still in the process of verifying and finalizing information related to the valuation and recording of long-lived assets, contingencies, tax accounts, and the resulting effects on the value of goodwill. As the Company finalizes the fair value of assets acquired and liabilities assumed, additional opening balance sheet adjustments will be recorded. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company's results of operations. The finalization of the opening balance sheet will result in a change in the valuation of assets acquired and liabilities assumed and may have a material impact on the Company's results of operations and financial position. The preliminary fair values of the assets acquired and liabilities assumed in connection with the Transactions are as follows: (estimated in millions) January 26, 2015 (as previously reported) Adjustments January 26, 2015 (as adjusted) Accounts receivable $ 1,349 $ — $ 1,349 Inventories 2,222 (1 ) 2,221 Other current assets 2,949 185 3,134 Property, plant, and equipment 2,354 (21 ) 2,333 Goodwill 29,586 22 29,608 Intangible assets 26,265 (71 ) 26,194 Other assets 747 24 771 Total assets acquired 65,472 138 65,610 Short-term borrowings 1,011 — 1,011 Other current liabilities 2,331 87 2,418 Long-term debt 4,623 — 4,623 Long-term deferred tax liabilities 4,736 73 4,809 Other long-term liabilities 2,783 (22 ) 2,761 Total liabilities assumed 15,484 138 15,622 Net assets acquired $ 49,988 $ — $ 49,988 Contingent liabilities assumed as part of the Transactions total $2.2 billion and are included within accrued income taxes , other accrued expenses , long-term accrued income taxes , and other long-term liabilities in the condensed consolidated balance sheet. These contingent liabilities include $1.5 billion related to income taxes (including uncertain tax positions and guarantee commitments), $0.5 billion related to legal claims (including product liability), and $0.2 billion related to environmental matters. Contingent liabilities are recorded at their estimated fair values, aside from those pertaining to uncertainty in income taxes which are an exception to the fair value basis of accounting. Legal matters and certain environmental matters that are legal in nature are recorded at their respective probable and estimable amounts. See Note 16 to the condensed consolidated financial statements for additional background on contingent liabilities. The estimated fair values noted above are preliminary and are subject to change upon finalization of the purchase accounting assessment and may have a material impact on the Company's results of operations and financial position. For additional information related to the Transactions, see Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . Fiscal Year 2016 The fair values of the assets acquired and liabilities assumed during the six months ended October 30, 2015 are as follows: (in millions) Twelve, Inc. RF Surgical Systems, Inc. Medina Medical All Other Total Other current assets $ 60 $ 43 $ 11 $ 33 $ 147 Property, plant, and equipment — 3 — 4 7 IPR&D 192 — 122 108 422 Other intangible assets — 115 — 120 235 Goodwill 301 132 126 170 729 Other assets — 2 — 6 8 Total assets acquired 553 295 259 441 1,548 Current liabilities 37 28 6 17 88 Long-term deferred tax liabilities, net 44 27 34 29 134 Other liabilities — — — 2 2 Total liabilities assumed 81 55 40 48 224 Net assets acquired $ 472 $ 240 $ 219 $ 393 $ 1,324 Twelve, Inc. On October 2, 2015, the Company's Coronary & Structural Heart division acquired Twelve, Inc. (Twelve), a privately-held medical device company focused on the development of a transcatheter mitral valve replacement device. Total consideration for the transaction was approximately $472 million , which included an upfront payment of $428 million and the estimated fair value of product development-based contingent consideration of $44 million . Based upon a preliminary acquisition valuation, the Company acquired $192 million of IPR&D and $301 million of goodwill. The acquired goodwill is not deductible for tax purposes. RF Surgical Systems, Inc. On August 11, 2015, the Company's Surgical Solutions division acquired RF Surgical Systems, Inc. (RF Surgical), a medical device company focused on the detection and prevention of retained surgical sponges. Total consideration for the transaction was approximately $240 million . Based upon a preliminary acquisition valuation, the Company acquired $68 million of technology-based intangible assets, $47 million of customer-related intangible assets, with estimated useful lives of 18 and 15 years, respectively, and $132 million of goodwill. The acquired goodwill is not deductible for tax purposes. Medina Medical On August 31, 2015, the Company's Neurovascular division acquired Medina Medical (Medina), a privately-held medical device company focused on commercializing treatments for vascular abnormalities of the brain, including cerebral aneurysms. Total consideration for the transaction was approximately $219 million , which includes an upfront payment of $155 million and the estimated fair value of revenue-based and product development-based contingent consideration of $64 million . Medtronic had previously invested in Medina and held an 11 percent ownership position. Net of this ownership position, the transaction value was approximately $195 million . Based upon a preliminary acquisition valuation, the Company acquired $122 million of IPR&D and $126 million of goodwill. The acquired goodwill is not deductible for tax purposes. The Company accounted for the acquisitions of Twelve, RF Surgical, and Medina and all other acquisitions as business combinations using the acquisition method of accounting. Acquisition-Related Items During the three and six months ended October 30, 2015 , the Company recorded acquisition-related items of $49 million and $120 million , respectively, primarily due to integration related costs incurred in connection with the Covidien acquisition, partially offset by income related to the change in fair value of contingent consideration associated with acquisitions subsequent to April 29, 2009. Fiscal Year 2015 The fair values of the assets acquired and liabilities assumed from acquisitions during fiscal year 2015, other than the Covidien acquisition, are as follows: (in millions) NGC Medical S.p.A. Sapiens Steering Brain Stimulation All Other Total Other current assets $ 55 $ 3 $ 12 $ 70 Property, plant, and equipment 15 1 2 18 IPR&D — 30 41 71 Other intangible assets 159 — 157 316 Goodwill 197 170 106 473 Other assets 3 3 49 55 Total assets acquired 429 207 367 1,003 Current liabilities 34 4 6 44 Long-term deferred tax liabilities, net 51 — 66 117 Other liabilities 4 — — 4 Total liabilities assumed 89 4 72 165 Net assets acquired $ 340 $ 203 $ 295 $ 838 The Company accounted for the acquisitions above as business combinations using the acquisition method of accounting. Other Acquisitions and Acquisition-Related Items During the three and six months ended October 24, 2014 , the Company recorded acquisition-related items of $61 million and $102 million , respectively, primarily due to costs incurred in connection with the Covidien acquisition. Contingent Consideration Certain of the Company’s business combinations and purchases of intellectual property involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. For business combinations subsequent to April 24, 2009, a liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. For business combinations or purchases of intellectual property prior to April 24, 2009, the estimated maximum amount of undiscounted future contingent consideration payments that the Company expected to make was approximately $191 million at October 30, 2015 . The Company estimates the milestones or other conditions associated with the contingent consideration will be reached in fiscal year 2016 and thereafter. The fair value of the contingent consideration is remeasured at each reporting period and the change in fair value recognized as income or expense within acquisition-related items in the condensed consolidated statements of income. The Company measures the liability on a recurring basis using Level 3 inputs. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Increases (decreases) in projected revenues, probabilities of payment, discount rates, or projected payment dates may result in a higher (lower) fair value measurement. Fluctuations in any of the inputs may result in a significantly lower (higher) fair value measurement. The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at ($ in millions) October 30, 2015 Valuation Technique Unobservable Input Range Discount rate 11% - 27.2% Revenue-based payments $203 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2016 - 2025 Discount rate 0.6% - 5.5% Product development-based payments $165 Discounted cash flow Probability of payment 15% - 100% Projected fiscal year of payment 2016 - 2020 The fair value of contingent consideration associated with acquisitions subsequent to April 24, 2009, as of October 30, 2015 and April 24, 2015 , was $368 million and $264 million , respectively. As of October 30, 2015 , $313 million was reflected in other long-term liabilities and $55 million was reflected in other accrued expenses in the condensed consolidated balance sheets. As of April 24, 2015 , $242 million was reflected in other long-term liabilities and $22 million was reflected in other accrued expenses in the condensed consolidated balance sheets. The portion of the contingent consideration paid related to the acquisition date fair value is reported as financing activities in the condensed consolidated statements of cash flows. Amounts paid in excess of the original acquisition date fair value are reported as operating activities in the condensed consolidated statements of cash flows. The following table provides a reconciliation of the beginning and ending balances of contingent consideration associated with acquisitions subsequent to April 24, 2009: Three months ended Six months ended (in millions) October 30, 2015 October 24, 2014 October 30, 2015 October 24, 2014 Beginning Balance $ 291 $ 87 $ 264 $ 68 Purchase price contingent consideration 109 — 135 23 Contingent consideration payments (17 ) — (20 ) (5 ) Change in fair value of contingent consideration (15 ) 4 (11 ) 5 Ending Balance $ 368 $ 91 $ 368 $ 91

Special Charges and Certain Lit

Special Charges and Certain Litigation Charges	6 Months Ended
	Oct. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Special Charges and Certain Litigation Charges	Special Charges and Certain Litigation Charges Special Charges During the three and six months ended October 30, 2015 , there were no special charges. During the three and six months ended October 24, 2014 , continuing the Company's commitment to improving the health of people and communities throughout the world, the Company made a $100 million charitable cash contribution to meet the multi-year funding needs of the Medtronic Foundation, a related party non-profit organization. Certain Litigation Charges The Company classifies material litigation reserves and gains recognized as certain litigation charges. During the three and six months ended October 30, 2015 , we recorded certain litigation charges of $26 million , which relates to probable and reasonably estimable INFUSE product liability litigation. During the three and six months ended October 24, 2014 , there were no certain litigation charges.

Restructuring Charges, Net

Restructuring Charges, Net	6 Months Ended
	Oct. 30, 2015
Restructuring Charges [Abstract]
Restructuring Charges, Net	Restructuring Charges, Net Cost Synergies Initiative The cost synergies initiative, initially referred to as the fiscal year 2015 initiative, was the beginning of the Company's restructuring program primarily related to the acquisition of Covidien. This initiative is expected to contribute to the approximately $850 million in cost synergies expected to be achieved as a result of the Covidien acquisition through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, certain program cancellations, and certain general and administrative savings. Restructuring charges are expected to be incurred on a quarterly basis throughout fiscal year 2016 and in future fiscal years as cost synergy initiatives are finalized. In the second quarter of fiscal year 2016, the Company recorded an $86 million restructuring charge in connection with the cost synergies initiative, which consisted primarily of employee termination costs of $64 million , asset write-downs of $10 million , and other related costs of $12 million . In the fourth quarter of fiscal year 2015, the Company recorded a $248 million restructuring charge, which consisted of employee termination costs of $213 million , asset write-downs of $28 million , contract termination costs of $6 million , and other related costs of $1 million . Of the $28 million of asset write-downs, $15 million related to inventory write-offs of discontinued product lines and production-related asset impairments, and therefore, was recorded within cost of products sold in the consolidated statements of income. In the first quarter of fiscal year 2016, the Company recorded a $67 million restructuring charge in connection with the cost synergies initiative, which consisted primarily of employee termination costs of $52 million and other related costs of $15 million . Restructuring accruals resulting from quarterly restructuring charges incurred within the cost synergies initiative are scheduled to be substantially complete within one year from the quarter the restructuring charge was initially incurred. As a result of certain employees identified for elimination finding other positions within the Company and revisions to particular strategies, the Company recorded a $13 million reversal of excess restructuring reserves in the second quarter of fiscal year 2016. As part of the cost synergies initiative, the Company recorded a $10 million impairment of property, plant, and equipment during the three and six months ended October 30, 2015 . The Company did not record any significant impairments of property, plant, and equipment during the three months ended October 24, 2014 . As part of the Company’s restructuring initiatives, the Company recorded property, plant, and equipment impairments of $9 million during the six months ended October 24, 2014 . A summary of the activity related to the cost synergies initiative is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total Balance as of April 24, 2015 $ 136 $ — $ 7 $ 143 Restructuring charges 52 — 15 67 Payments/write-downs (76 ) — (7 ) (83 ) Balance as of July 31, 2015 $ 112 $ — $ 15 $ 127 Restructuring charges 64 10 12 86 Payments/write-downs (28 ) (10 ) (6 ) (44 ) Reversal of excess accrual (13 ) — — (13 ) Balance as of October 30, 2015 $ 135 $ — $ 21 $ 156 Covidien Initiative Covidien's pre-acquisition restructuring program is designed to improve legacy Covidien's cost structure. The program consists of reducing corporate expenses, expanding shared services, consolidating manufacturing locations, and optimizing distribution centers. The Covidien restructuring initiative is scheduled to be substantially complete by the end of fiscal year 2018. At the Acquisition Date, the Company reserved $103 million in connection with the Covidien initiative, which consisted of employee termination costs of $76 million and other costs of $27 million . In the fourth quarter of fiscal year 2015, the Company recorded a reversal of excess restructuring reserves related to the Covidien initiative of $5 million . The reversals were primarily the result of certain employees identified for elimination finding other positions within the Company and revisions to particular strategies. A summary of the activity related to the Covidien initiative is presented below: (in millions) Employee Termination Costs Other Costs Total Balance as of April 24, 2015 $ 61 $ 17 $ 78 Payments (13 ) (5 ) (18 ) Balance as of July 31, 2015 $ 48 $ 12 $ 60 Payments (8 ) (6 ) (14 ) Balance as of October 30, 2015 $ 40 $ 6 $ 46

Financial Instruments

Financial Instruments	6 Months Ended
	Oct. 30, 2015
Investments [Abstract]
Financial Instruments	Financial Instruments The Company holds investments consisting primarily of marketable debt and equity securities. The authoritative guidance is principally applied to financial assets and liabilities such as marketable equity securities and debt and equity securities that are classified and accounted for as trading and available-for-sale and are measured on a recurring basis. Further, we also hold cost or equity method investments which are measured at fair value on a nonrecurring basis. The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at October 30, 2015 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities Level 1: U.S. government and agency securities $ 1,696 $ 7 $ (4 ) $ 1,699 $ 1,699 $ — Marketable equity securities 79 23 (3 ) 99 — 99 Total Level 1 1,775 30 (7 ) 1,798 1,699 99 Level 2: Corporate debt securities 6,618 50 (56 ) 6,612 6,612 — U.S. government and agency securities 1,537 3 (3 ) 1,537 1,537 — Mortgage-backed securities 1,466 14 (14 ) 1,466 1,466 — Foreign government and agency securities 65 — — 65 65 — Certificates of deposit 47 — — 47 47 — Other asset-backed securities 510 2 — 512 512 — Debt funds 3,148 6 (322 ) 2,832 2,832 — Total Level 2 13,391 75 (395 ) 13,071 13,071 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (7 ) 102 — 102 Total Level 3 110 — (7 ) 103 — 103 Total available-for-sale securities 15,276 105 (409 ) 14,972 14,770 202 Trading securities: Level 1: Exchange-traded funds 65 16 — 81 81 — Total Level 1: 65 16 — 81 81 — Total trading securities 65 16 — 81 81 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 484 — — N/A — 484 Total Level 3: 484 — — N/A — 484 Total cost method, equity method, and other investments 484 — — N/A — 484 Total investments $ 15,825 $ 121 $ (409 ) $ 15,053 $ 14,851 $ 686 The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at April 24, 2015 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 1,525 $ 17 $ (1 ) $ 1,541 $ 1,541 $ — Marketable equity securities 64 35 (19 ) 80 — 80 Total Level 1 1,589 52 (20 ) 1,621 1,541 80 Level 2: Corporate debt securities 6,282 105 (10 ) 6,377 6,377 — U.S. government and agency securities 1,597 4 (3 ) 1,598 1,598 — Mortgage-backed securities 1,462 22 (6 ) 1,478 1,478 — Foreign government and agency securities 85 — — 85 85 — Certificates of deposit 44 — — 44 44 — Other asset-backed securities 504 3 — 507 507 — Debt funds 3,061 19 (150 ) 2,930 2,930 — Total Level 2 13,035 153 (169 ) 13,019 13,019 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (4 ) 105 — 105 Total Level 3 110 — (4 ) 106 — 106 Total available-for-sale securities 14,734 205 (193 ) 14,746 14,560 186 Trading securities: Level 1: Exchange-traded funds 58 19 — 77 77 — Total Level 1 58 19 — 77 77 — Total trading securities 58 19 — 77 77 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 520 — — N/A — 520 Total Level 3 520 — — N/A — 520 Total cost method, equity method, and other investments 520 — — N/A — 520 Total investments $ 15,312 $ 224 $ (193 ) $ 14,823 $ 14,637 $ 706 Marketable Debt and Equity Securities: The following tables show the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category as of October 30, 2015 and April 24, 2015 : October 30, 2015 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 2,932 $ (50 ) $ 183 $ (6 ) Auction rate securities — — 102 (7 ) Mortgage-backed securities 622 (10 ) 225 (4 ) U.S. government and agency securities 1,146 (5 ) 142 (2 ) Debt funds 1,190 (93 ) 1,128 (229 ) Marketable equity securities 26 (3 ) — — Total $ 5,916 $ (161 ) $ 1,780 $ (248 ) April 24, 2015 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 944 $ (9 ) $ 34 $ (1 ) Auction rate securities — — 105 (4 ) Mortgage-backed securities 346 (3 ) 206 (3 ) U.S. government and agency securities 356 (1 ) 267 (3 ) Debt funds 1,291 (109 ) 559 (41 ) Marketable equity securities 4 (19 ) — — Total $ 2,941 $ (141 ) $ 1,171 $ (52 ) The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 as of October 30, 2015 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6% The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and six months ended October 30, 2015 or October 24, 2014 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended October 30, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of July 31, 2015 $ 103 $ 1 $ 102 Total unrealized gains included in other comprehensive income — — — Balance as of October 30, 2015 $ 103 $ 1 $ 102 Three months ended October 24, 2014 (in millions) Total Level 3 Corporate debt Auction rate Balance as of July 25, 2014 $ 108 $ 9 $ 99 Total unrealized gains included in other comprehensive income — — — Balance as of October 24, 2014 $ 108 $ 9 $ 99 Six months ended October 30, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2015 $ 106 $ 1 $ 105 Total unrealized losses included in other comprehensive income (3 ) — (3 ) Balance as of October 30, 2015 $ 103 $ 1 $ 102 Six months ended October 24, 2014 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2014 $ 106 $ 9 $ 97 Total unrealized gains included in other comprehensive income 2 — 2 Balance as of October 24, 2014 $ 108 $ 9 $ 99 Activity related to the Company’s investment portfolio is as follows: Three months ended October 30, 2015 October 24, 2014 (in millions) Debt (a) Equity (b) (c) Debt (a) Equity (b) (d) Proceeds from sales $ 1,481 $ 5 $ 806 $ 7 Gross realized gains 4 20 4 39 Gross realized losses (7 ) — (2 ) — Impairment losses recognized — (19 ) — (20 ) Six months ended October 30, 2015 October 24, 2014 (in millions) Debt (a) Equity (b) (c) Debt (a) Equity (b) (e) Proceeds from sales $ 2,718 $ 34 $ 2,636 $ 29 Gross realized gains 9 32 16 58 Gross realized losses (12 ) — (5 ) — Impairment losses recognized — (42 ) — (20 ) (a) Includes available-for-sale debt securities. (b) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments. (c) As a result of certain acquisitions that occurred during the three and six months ended October 30, 2015 , the Company recognized a non-cash realized gain of $9 million on its previously-held minority investment included in other expense, net on the condensed consolidated statement of income. (d) As a result of certain acquisitions that occurred during the three months ended October 24, 2014 , the Company recognized a non-cash realized gain of $35 million on its previously-held minority investment included in other expense, net on the condensed consolidated statement of income. (e) As a result of certain acquisitions that occurred during the six months ended October 24, 2014 , the Company recognized a non-cash realized gain of $41 million on its previously-held minority investments included in other expense, net on the condensed consolidated statement of income. Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which invested, the Company believes it has recorded all necessary other-than-temporary impairments as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. As of October 30, 2015 and April 24, 2015 , the credit loss portion of other-than temporary impairments on debt securities were not significant. The total reductions for available-for-sale debt securities sold during the three and six months ended October 30, 2015 and October 24, 2014 were not significant. The total other-than-temporary impairment losses on available-for-sale debt securities for the three and six months ended October 30, 2015 and October 24, 2014 were not significant. The October 30, 2015 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) October 30, 2015 Due in one year or less $ 2,245 Due after one year through five years 6,314 Due after five years through ten years 3,197 Due after ten years 285 Total $ 12,041 The Company holds investments in marketable equity securities, which are classified as other assets in the condensed consolidated balance sheets. The aggregate carrying amount of these investments was $99 million and $80 million as of October 30, 2015 and April 24, 2015 , respectively. The Company did not record any significant impairment charges related to marketable equity securities during the three months ended October 30, 2015 . During the six months ended October 30, 2015 , the Company determined that the fair value of certain marketable equity securities were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $20 million in impairment charges for the six months ended October 30, 2015 , which were recorded within other expense, net in the condensed consolidated statements of income. During the three and six months ended October 24, 2014 , the Company determined that the fair value of certain marketable equity securities were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $7 million in impairment charges for the three and six months ended October 24, 2014, which were recorded in other expense, net in the condensed consolidated statements of income. Cost method, equity method, and other investments The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the condensed consolidated balance sheets. As of October 30, 2015 and April 24, 2015 , the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $484 million and $520 million , respectively. These cost or equity method investments are measured at fair value on a nonrecurring basis. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment. During the three and six months ended October 30, 2015 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $19 million and $21 million in impairment charges during the three and six months ended October 30, 2015 , respectively, which were recorded in other expense, net in the condensed consolidated statements of income. During the three and six months ended October 24, 2014 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $13 million in impairment charges during the three and six months ended October 24, 2014 , which were recorded in other expense, net in the condensed consolidated statements of income. These investments fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value, as the investments are privately-held entities without quoted market prices. To determine the fair value of these investments, the Company used all pertinent financial information available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings.

Financing Arrangements

Financing Arrangements	6 Months Ended
	Oct. 30, 2015
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.500 billion in commercial paper outstanding, with maturities up to 364 days from the date of issuance. Commercial paper amounts outstanding as of October 30, 2015 totaled $1.307 billion . No amounts were outstanding as of April 24, 2015 . During the three and six months ended October 30, 2015 , the weighted average original maturity of the commercial paper outstanding was approximately 47 days and 45 days, respectively, and the weighted average interest rate was 0.44 percent and 0.42 percent, respectively. The issuance of commercial paper proportionately reduced the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.500 billion five year credit facility (Credit Facility) which provides back up funding for the commercial paper program described above. As of October 30, 2015 and April 24, 2015 , no amounts were outstanding. Interest rates are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company remained in compliance with as of October 30, 2015 . Long-Term Debt Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year Payable as of October 30, 2015 Payable as of April 24, 2015 Floating rate three-year 2014 senior notes 2017 $ 250 $ 250 0.875 percent three-year 2014 senior notes 2017 250 250 6.000 percent ten-year 2008 CIFSA senior notes 2018 1,150 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 1,250 1,250 4.200 percent ten-year 2010 CIFSA senior notes 2020 600 600 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.200 percent ten-year 2012 CIFSA senior notes 2022 650 650 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 2.750 percent ten-year 2013 senior notes 2023 1,250 1,250 2.950 percent ten-year 2013 CIFSA senior notes 2023 750 750 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,500 2,500 6.550 percent thirty-year 2007 CIFSA senior notes 2037 850 850 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 750 750 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 3,000 3,000 Interest rate swaps (Note 8) 2017 - 2022 72 79 Deferred gains from interest rate swap terminations, net - — 3 Capital lease obligations 2017 - 2025 121 129 Bank borrowings 2021 32 17 Debt premium 2017 - 2045 440 499 Total Long-Term Debt $ 33,690 $ 33,752 Senior Notes The Company has outstanding unsecured senior obligations including those indicated as senior notes in the long-term debt table above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remains in compliance with as of October 30, 2015 . The Company used the net proceeds from the sale of the Senior Notes primarily for working capital and general corporate uses, which includes the repayment of other indebtedness of the Company, and to fund the acquisition of Covidien in fiscal year 2015. For additional information regarding the terms of these agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . Financial Instruments Not Measured at Fair Value As of October 30, 2015 , the total estimated fair value of the Company’s long-term debt, including the short-term portion, was $31.913 billion compared to a principal value of $30.525 billion ; as of April 24, 2015 , the total estimated fair value was $34.637 billion compared to a principal value of $32.125 billion . The fair value was estimated using quoted market prices for the publicly registered senior notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and derivative/hedging activity.

Derivatives and Foreign Exchang

Derivatives and Foreign Exchange Risk Management	6 Months Ended
	Oct. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Foreign Exchange Risk Management	Derivatives and Foreign Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding at October 30, 2015 and April 24, 2015 was $10.086 billion and $9.782 billion , respectively. The aggregate currency exchange rate gains for the three and six months ended October 30, 2015 were $55 million and $98 million , respectively. The aggregate currency exchange rate gains for the three and six months ended October 24, 2014 were $14 million and $2 million , respectively. The information that follows explains the various types of derivatives and financial instruments used by the Company, how and why the Company uses such instruments, and how such instruments impact the Company’s condensed consolidated balance sheets, statements of income, and statements of cash flows. Freestanding Derivative Contracts Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in a foreign currency. The gross notional amount of these contracts, not designated as hedging instruments, outstanding at October 30, 2015 and April 24, 2015 , was $3.653 billion and $4.713 billion , respectively. The amount and location of the gains (losses) in the condensed consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and six months ended October 30, 2015 and October 24, 2014 are as follows: (in millions) Three months ended Derivatives Not Designated as Hedging Instruments Location October 30, 2015 October 24, 2014 Foreign currency exchange rate contracts gains (losses) Other expense, net $ (4 ) $ 73 (in millions) Six months ended Derivatives Not Designated as Hedging Instruments Location October 30, 2015 October 24, 2014 Foreign currency exchange rate contracts gains (losses) Other expense, net $ 16 $ 49 Cash Flow Hedges Foreign Currency Exchange Rate Risk Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. No gains or losses relating to ineffectiveness of foreign currency cash flow hedges were recognized in earnings during the three or six months ended October 30, 2015 or October 24, 2014 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three or six months ended October 30, 2015 or October 24, 2014 . The gross notional amount of these contracts, designated as cash flow hedges, outstanding at October 30, 2015 and April 24, 2015 , were $6.433 billion and $5.069 billion , respectively, and will mature within the subsequent three -year period. The amount of gains (losses) and location of the gains (losses) in the condensed consolidated statements of income and other comprehensive income (OCI) related to foreign currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended October 30, 2015 and October 24, 2014 are as follows: Three months ended October 30, 2015 Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 17 Other expense, net $ 89 Cost of products sold (15 ) Total $ 17 $ 74 Three months ended October 24, 2014 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 229 Other expense, net $ 20 Cost of products sold 1 Total $ 229 $ 21 Six months ended October 30, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 3 Other expense, net $ 184 Cost of products sold (36 ) Total $ 3 $ 148 Six months ended October 24, 2014 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 291 Other expense, net $ 21 Cost of products sold (2 ) Total $ 291 $ 19 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in earnings during the three or six months ended October 30, 2015 or October 24, 2014 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three or six months ended October 30, 2015 or October 24, 2014 . During the second quarter of fiscal year 2016, the Company terminated forward starting interest rate derivatives with a consolidated notional amount of $500 million , which were previously entered into in advance of a planned debt issuance that is no longer expected post the Internal Reorganization defined in Note 11 to the condensed consolidated financial statements . Upon termination, these swaps were in a net liability position, resulting in a cash payment of $45 million . As of October 30, 2015 , the Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed-rate of 3.10 percent in anticipation of planned debt issuances in fiscal year 2017. For the three and six months ended October 30, 2015 , the Company reclassified $3 million and $6 million , respectively, of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net . For the three and six months ended October 24, 2014 , the Company reclassified $2 million and $4 million , respectively, of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net . The unrealized losses on outstanding forward starting interest rate swap derivative instruments as of October 30, 2015 and April 24, 2015 were $27 million and $71 million , respectively. Unrealized losses on outstanding forward starting interest rate swap derivative instruments were recorded in other long-term liabilities, with the offset recorded in accumulated other comprehensive loss in the condensed consolidated balance sheets. As of October 30, 2015 and April 24, 2015 , the Company had $154 million and $210 million , respectively, in after-tax net unrealized gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $166 million of after-tax net unrealized gains as of October 30, 2015 will be reclassified into the condensed consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. As of both October 30, 2015 and April 24, 2015 , the Company had interest rate swaps in gross notional amounts of $1.425 billion and $2.025 billion , respectively, designated as fair value hedges of underlying fixed-rate senior note obligations. For additional information regarding the terms of the Company’s interest rate swap agreements, refer to Note 9 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . The market value of outstanding interest rate swap agreements was a net $47 million unrealized gain, and the market value of the hedged item was a net $47 million unrealized loss at October 30, 2015 , which were recorded in other assets, prepaid expenses and other current assets, and other long-term liabilities with the offsets recorded in long-term debt and short-term borrowings in the condensed consolidated balance sheets. No hedge ineffectiveness was recorded as a result of these fair value hedges for the three or six months ended October 30, 2015 or October 24, 2014 . During the three and six months ended October 30, 2015 and October 24, 2014 , the Company did not have any significant ineffective fair value hedging instruments. In addition, the Company did not recognize any significant gains or losses during the three or six months ended October 30, 2015 or October 24, 2014 on firm commitments that no longer qualify as fair value hedges. Balance Sheet Presentation The following tables summarize the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets as of October 30, 2015 and April 24, 2015 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. October 30, 2015 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 2 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 286 Other accrued expenses 18 Interest rate contracts Other assets 72 Other long-term liabilities 72 Foreign currency exchange rate contracts Other assets 89 Other long-term liabilities 5 Total derivatives designated as hedging instruments $ 449 $ 95 Derivatives not designated as hedging instruments Commodity derivatives Prepaid expenses and $ — Other accrued expenses $ 9 Foreign currency exchange rate contracts Prepaid expenses and other current assets 28 Other accrued expenses 24 Cross currency interest rate contracts Other assets 21 Other long-term liabilities 4 Total derivatives not designated as hedging instruments $ 49 $ 37 Total derivatives $ 498 $ 132 April 24, 2015 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 10 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 382 Other accrued expenses 12 Interest rate contracts Other assets 79 Other long-term liabilities 71 Foreign currency exchange rate contracts Other assets 143 Other long-term liabilities 3 Total derivatives designated as hedging instruments $ 614 $ 86 Derivatives not designated as hedging instruments Foreign currency exchange rate contracts Prepaid expenses and other current assets $ 119 Other accrued expenses $ 30 Total derivatives not designated as hedging instruments $ 119 $ 30 Total derivatives $ 733 $ 116 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis as of October 30, 2015 and April 24, 2015: (in millions) October 30, 2015 April 24, 2015 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative Assets $ 403 $ 95 $ — $ 644 $ 89 $ — Derivative Liabilities 47 85 — 45 71 — The Company has elected to present the fair value of derivative assets and liabilities within the condensed consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 30, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 403 $ (66 ) $ (205 ) $ 132 Interest rate contracts 74 (8 ) (12 ) 54 Cross currency interest rate contracts 21 — — 21 $ 498 $ (74 ) $ (217 ) $ 207 Derivative Liabilities Foreign currency exchange rate contracts $ (47 ) $ 39 $ — $ (8 ) Interest rate contracts (72 ) 35 16 (21 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity derivatives (9 ) — — (9 ) $ (132 ) $ 74 $ 16 $ (42 ) Total $ 366 $ — $ (201 ) $ 165 April 24, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 644 $ (61 ) $ (325 ) $ 258 Interest rate contracts 89 (10 ) (13 ) 66 $ 733 $ (71 ) $ (338 ) $ 324 Derivative Liabilities Foreign currency exchange rate contracts $ (45 ) $ 31 $ — $ (14 ) Interest rate contracts (71 ) 40 8 (23 ) $ (116 ) $ 71 $ 8 $ (37 ) Total $ 617 $ — $ (330 ) $ 287

Inventories

Inventories	6 Months Ended
	Oct. 30, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments, or other economic factors. Inventory balances were as follows: (in millions) October 30, 2015 April 24, 2015 Finished goods $ 2,244 $ 2,268 Work in-process 527 509 Raw materials 745 686 Total $ 3,516 $ 3,463

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	6 Months Ended
	Oct. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	Goodwill and Other Intangible Assets, Net The changes in the carrying amount of goodwill for the six months ended October 30, 2015 are as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total Balance as of April 24, 2015 $ 5,855 $ 23,399 $ 9,424 $ 1,852 $ 40,530 Goodwill as a result of acquisitions 409 132 191 — 732 Purchase accounting adjustments, net 24 (9 ) 5 — 20 Currency adjustment, net (6 ) — (3 ) 1 (8 ) Balance as of October 30, 2015 $ 6,282 $ 23,522 $ 9,617 $ 1,853 $ 41,274 During the six months ended October 30, 2015 , the Company recorded $20 million of purchase accounting adjustments, net, primarily related to the Covidien acquisition. See Note 3 to the condensed consolidated financial statements for additional information on purchase accounting adjustments related to the Covidien acquisition. The gross carrying amount and accumulated amortization of intangible assets at October 30, 2015 and April 24, 2015 are as follows: October 30, 2015 April 24, 2015 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Customer-related $ 18,579 $ (801 ) $ 18,492 $ (273 ) Purchased technology and patents 11,265 (2,560 ) 11,118 (2,268 ) Trademarks and tradenames 850 (408 ) 640 (363 ) Other 84 (47 ) 79 (44 ) Total $ 30,778 $ (3,816 ) $ 30,329 $ (2,948 ) Non-Amortizable: IPR&D $ 769 $ 470 Tradenames — 250 Total $ 769 $ 720 Amortization expense for the three and six months ended October 30, 2015 was $483 million and $964 million , respectively, and for the three and six months ended October 24, 2014 was $89 million and $176 million , respectively. Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets as of October 30, 2015 , excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows: (in millions) Fiscal Year Estimated Amortization Expense Remaining 2016 $ 964 2017 1,913 2018 1,882 2019 1,789 2020 1,741 2021 1,724 The Company assesses the impairment of goodwill annually in the third quarter at the reporting unit level and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of goodwill was $41.274 billion and $40.530 billion as of October 30, 2015 and April 24, 2015 , respectively. The Company did not record any goodwill impairment during the three and six months ended October 30, 2015 or October 24, 2014 . The Company assesses IPR&D for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of IPR&D was $769 million and $470 million as of October 30, 2015 and April 24, 2015 , respectively. Similar to the goodwill impairment test, the IPR&D impairment test requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of IPR&D asset fair values over their carrying values utilizing a discounted future cash flow analysis. During the three and six months ended October 30, 2015 and October 24, 2014 , the Company did not record any significant IPR&D impairments. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may record impairment losses in the future. The Company assesses intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. The aggregate carrying amount of intangible assets, excluding IPR&D and non-amortizable tradenames, was $26.962 billion and $27.381 billion as of October 30, 2015 and April 24, 2015 , respectively. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recorded based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not record any significant intangible asset impairments during the three and six months ended October 30, 2015 or October 24, 2014 .

Income Taxes

Income Taxes	6 Months Ended
	Oct. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the second quarter of fiscal year 2016, the Company recorded a $442 million tax charge primarily associated with the Internal Reorganization, as defined below, of the ownership of certain legacy Covidien businesses. This charge was recorded within provision for income taxes in the condensed consolidated statements of income. The Company’s effective tax rates for the three and six months ended October 30, 2015 were 52.0 percent and 33.8 percent, respectively, compared to 19.0 percent and 19.3 percent for the three and six months ended October 24, 2014 , respectively. The change in the Company’s effective tax rate for the three and six months ended October 30, 2015 was primarily due to the impact of certain tax adjustments of $442 million , which largely relates to U.S. income tax expense resulting from our completion of an internal reorganization of the ownership of certain legacy Covidien businesses that reduced the cash and investments held by our U.S.-controlled non-U.S. subsidiaries (the Internal Reorganization). The change was also attributable to the impact of special charges, restructuring charges, net, acquisition-related items, the other effects of the acquisition of Covidien, and year over year changes in operational results by jurisdiction. During the six months ended October 30, 2015 , the Company's gross unrecognized tax benefits decreased from $2.860 billion to $2.602 billion . In addition, the Company has accrued gross interest and penalties of $588 million as of October 30, 2015 . If all of the Company’s unrecognized tax benefits were recognized, approximately $2.022 billion would impact the Company’s effective tax rate. The Company has recorded $5 million of gross unrecognized tax benefits as a current liability and $2.597 billion as a long-term liability. The Company will continue to recognize interest and penalties related to income tax matters within provision for income taxes in the condensed consolidated statements of income and record the liability within accrued income taxes or long-term accrued income taxes in the condensed consolidated balance sheets, as appropriate. See Note 16 to the condensed consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Oct. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares, issued as part of the Transactions, are considered a participating security. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended Six months ended (in millions, except per share data) October 30, October 24, October 30, October 24, Numerator: Net income attributable to ordinary shareholders $ 520 $ 828 $ 1,340 $ 1,699 Denominator: Basic – weighted average shares outstanding 1,412.9 981.9 1,415.6 987.5 Effect of dilutive securities: Employee stock options 12.2 7.3 12.7 7.4 Employee restricted stock units 3.6 3.7 4.3 4.4 Other 0.1 0.1 0.1 0.1 Diluted – weighted average shares outstanding 1,428.8 993.0 1,432.7 999.4 Basic earnings per share $ 0.37 $ 0.84 $ 0.95 $ 1.72 Diluted earnings per share $ 0.36 $ 0.83 $ 0.94 $ 1.70 The calculation of weighted average diluted shares outstanding excludes approximately 6 million and 3 million options for the three and six months ended October 30, 2015 , respectively, and approximately 4 million and 2 million options for the three and six months ended October 24, 2014 , respectively, because their effect would have been anti-dilutive on the Company’s earnings per share. Additionally, the calculation of weighted average diluted shares outstanding excludes approximately 22 million and 21 million shares for the three and six months ended October 30, 2015 , respectively, and approximately 1 million restricted stock units for both the three and six months ended October 24, 2014 , respectively, because the performance criteria had not yet been met.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Oct. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The following table presents the components and classification of stock-based compensation expense recognized for the three and six months ended October 30, 2015 and October 24, 2014 : Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Stock options $ 62 $ 14 $ 119 $ 20 Restricted stock awards 46 31 80 54 Employee stock purchase plan 5 3 10 8 Total stock-based compensation expense $ 113 $ 48 $ 209 $ 82 Cost of products sold $ 14 $ 4 $ 26 $ 8 Research and development expense 12 9 20 15 Selling, general, and administrative expense 65 35 114 59 Restructuring charges, net 6 — 14 — Acquisition-related items 16 — 35 — Total stock-based compensation expense $ 113 $ 48 $ 209 $ 82 Income tax benefits (34 ) (14 ) (63 ) (23 ) Total stock-based compensation expense, net of tax $ 79 $ 34 $ 146 $ 59

Retirement Benefit Plans

Retirement Benefit Plans	6 Months Ended
	Oct. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 30, 2015 and October 24, 2014 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) October 30, October 24, October 30, October 24, Service cost $ 30 $ 26 $ 22 $ 15 Interest cost 31 26 9 8 Expected return on plan assets (45 ) (39 ) (13 ) (10 ) Amortization of net actuarial loss 24 16 6 3 Net periodic benefit cost $ 40 $ 29 $ 24 $ 16 U.S. Pension Benefits Non-U.S. Pension Benefits Six months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Service cost $ 60 $ 52 $ 44 $ 30 Interest cost 62 52 18 16 Expected return on plan assets (90 ) (78 ) (26 ) (20 ) Amortization of net actuarial loss 48 32 12 6 Net periodic benefit cost $ 80 $ 58 $ 48 $ 32

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Oct. 30, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (302 ) (59 ) (5 ) 44 (322 ) Tax benefit (expense) 108 — — (17 ) 91 Other comprehensive (loss) income before reclassifications, net of tax (194 ) (59 ) (5 ) 27 (231 ) Reclassifications, before tax (20 ) — 60 (133 ) (93 ) Tax benefit (expense) 7 — (20 ) 50 37 Reclassifications, net of tax (13 ) (b) — 40 (c) (83 ) (d) (56 ) Other comprehensive (loss) income, net of tax (207 ) (59 ) 35 (56 ) (287 ) Balance as of October 30, 2015, net of tax $ (193 ) $ (336 ) $ (1,096 ) $ 154 $ (1,471 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 25, 2014, net of tax $ (6 ) $ 218 $ (765 ) $ (44 ) $ (597 ) Other comprehensive income (loss) before reclassifications, before tax 61 (129 ) 16 263 211 Tax expense (22 ) — — (93 ) (115 ) Other comprehensive income before reclassifications, net of tax 39 (129 ) 16 170 96 Reclassifications, before tax (28 ) — 38 (16 ) (6 ) Tax benefit (expense) 9 — (12 ) 4 1 Reclassifications, net of tax (19 ) (b) — 26 (c) (12 ) (d) (5 ) Other comprehensive income (loss), net of tax 20 (129 ) 42 158 91 Balance as of October 24, 2014, net of tax $ 14 $ 89 $ (723 ) $ 114 $ (506 ) (a) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (b) Represents net realized gains on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 6 ). (c) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 14 ). (d) Relates to foreign currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 8 ).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Oct. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and other matters. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief (including injunctions barring the sale of products that are the subject of the lawsuit), that could require significant expenditures or result in lost revenues. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines or punitive damages; or could result in a change in business practice. As of October 30, 2015 and April 24, 2015, accrued certain litigation charges involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, and other matters were $777 million and $879 million , respectively. The Company includes accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets. In addition to the litigation contingencies referenced below, the Company also has certain guarantee obligations that may potentially result in future costs. While it is not possible to predict the outcome for most of the matters discussed below, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. Product Liability Matters Sprint Fidelis In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. INFUSE Litigation The Company estimates law firms representing approximately 6,000 claimants have asserted or intend to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of December 1, 2015, the Company has reached agreements to settle approximately 3,900 of these claims. The Company recorded an additional expense of $ 26 million in the second quarter of fiscal year 2016, related to probable and reasonably estimated damages in connection with this matter. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Other INFUSE Litigation On June 5, 2014, Humana, Inc. filed a lawsuit for unspecified monetary damages in the U.S. District Court for the Western District of Tennessee, alleging that Medtronic, Inc. violated federal racketeering (RICO) law and various state laws, by conspiring with physicians to promote unapproved uses of INFUSE. On September 25, 2015, the Court granted Medtronic’s motion to dismiss the primary allegations, including the RICO claims, in Humana’s complaint. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Pelvic Mesh Litigation The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In July 2015, the Company and Bard agreed that Bard would pay the Company $121 million towards the settlement of these claims. The $121 million settlement was recorded as an opening balance sheet adjustment related to the Covidien acquisition in the first quarter of fiscal year 2016. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 11,500 claimants have asserted or intend to assert claims involving products manufactured by Covidien’s subsidiaries. As of December 1, 2015, the Company has reached agreements to settle approximately 4,200 of these claims. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Patent Litigation Ethicon On March 28, 2013, the federal court ruled in favor of Covidien in a patent infringement suit against Ethicon Endo-Surgery, Inc. (Ethicon), a Johnson & Johnson company, relating to Ethicon’s Harmonic ® line of ultrasonic surgical products. The federal court awarded Covidien $177 million in damages upon ruling that several of Covidien’s patents were valid, enforceable and infringed by Ethicon. Ethicon appealed the decision. On December 4, 2014, the U.S. Court of Appeals for the Federal Circuit reversed the $177 million judgment against Ethicon and ruled that the infringed patent claims were invalid. On July 27, 2015, the Company filed a request seeking Supreme Court review of the Federal Circuit’s decision in the case. On November 30, 2015, the Supreme Court denied the Company’s request for further review of the Federal Circuit’s decision in the case. Ethicon Endo-Surgery, Inc., et al. v. Covidien, Inc., et al . is a patent infringement action filed on December 14, 2011 in the U.S. District Court for the Southern District of Ohio, Western Division. The complaint alleges that Covidien’s Sonicision product infringes several of Ethicon’s design and utility patents. Ethicon is seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien’s favor, ruling that Covidien does not infringe any of the seven Ethicon patents in dispute and declaring five of Ethicon’s patents invalid. Ethicon appealed the district court’s decision and on August 7, 2015, the Court of Appeals for the Federal Circuit issued a ruling affirming in part, reversing in part, and vacating in part. Specifically, the decision upheld the finding that Sonicision does not infringe any of the four design patents asserted by Ethicon, upheld the claim construction on a patent related to ultrasonic dampening components but remanded to the trial court for further proceedings because of factual issues, and reversed the District Court’s finding that an Ethicon patent directed to ultrasonic shears and methods of sealing blood vessels was invalid. The case was remanded to the U.S. District Court for the Southern District of Ohio, Western Division and the case is currently stayed to allow the parties to pursue mediation on the remaining claims. The Company has not recorded an expense related to damages in connection with the patent litigation matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. Shareholder Related Matters INFUSE On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and members of its Board of Directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the Court denied Kokocinski’s request for reconsideration. Kokocinski has appealed the Court’s decision to the U.S. Court of Appeals for the Eighth Circuit. In May 2012, Daniel Himmel and the Saratoga Advantage Trust commenced two other separate shareholder derivative actions in Hennepin County, Minnesota, District Court against the same defendants, making allegations similar to those in the Kokocinski case. On July 1, 2014, Road Carriers Local 707 Welfare & Pension Funds filed a shareholder derivative action in Hennepin County, Minnesota, District Court against the same defendants making allegations similar to those in the Kokocinski, Himmel, and Saratoga Advantage Trust cases. On July 24, 2014, Anne Shirley Cutler filed a shareholder derivative action in Hennepin County, Minnesota, District Court against certain of the same defendants making allegations similar to those in the Kokocinski, Himmel, and Saratoga Advantage Trust cases as well as allegations that defendants violated purported duties in connection with the Synchromed pain pump system. On May 26, 2015, the Himmel , Saratoga Advantage Trust , Road Carriers Local 707 , and Cutler plaintiffs filed Voluntary Stipulations of Dismissal with Prejudice or statements of non-opposition to dismissal of all INFUSE-related claims and allegations. On June 4, 2015, the Court preliminarily approved the INFUSE-related dismissals with prejudice subject to shareholder notice and an opportunity to intervene. On June 9, 2015 and July 14, 2015, the Company provided notice of the Court's order in a Report on Form 8-K filing. No shareholder intervened within the deadline set by the Court. On October 6, 2015, the Court issued an order (the October 6 Order) approving the Cutler plaintiffs Voluntary Stipulations of Dismissal with Prejudice relating to the Synchromed pain pump system claims. With the issuance of the October 6 Order, all of the Himmel , Saratoga Advantage Trust , Road Carriers Local 707 , and Cutler cases have been dismissed with prejudice, bringing these matters to a conclusion without any findings of liability or damages against defendants. On September 26, 2014, Richard Hockstein filed an INFUSE-related shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and members of its Board of Directors in the U.S. District Court for the District of Minnesota making allegations similar to those in the Kokocinski case. On September 30, 2015, the Court granted defendants’ motion and dismissed the complaint with prejudice, bringing this matter to a conclusion without any findings of liability or damages against defendants. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September, 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit. Shareholder Related Matters Resulting from the Covidien Acquisition On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstei n and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and oral argument before the Minnesota State Court of Appeals occurred on October 29, 2015. Putative shareholder class action complaints have been filed in the U.S. District Court for the District of Massachusetts by purported shareholders of Covidien under the captions Taxman v. Covidien plc, et al ., 14-cv-12949, Lipovich v. Covidien plc, et al ., 14-cv-13308 and Rosenfeld Family Foundation v. Covidien plc, et al ., 14-cv-13490. On October 20, 2014, the plaintiff in the Rosenfeld action and another purported shareholder of Covidien filed a motion seeking to consolidate the Taxman, Lipovich and Rosenfeld actions, and on November 14, 2014, the U.S. District Court for the District of Massachusetts granted that motion consolidating the actions (the Consolidated Action). On December 23, 2014, the defendants reached an agreement in principle with plaintiffs in the Consolidated Action, and that agreement is reflected in a memorandum of understanding. In connection with the settlement contemplated by the memorandum of understanding, Covidien agreed to make certain additional disclosures related to the Transactions, which are contained in Covidien’s Report on Form 8-K filed on December 23, 2014. The memorandum of understanding contemplated that the parties would enter into a stipulation of settlement, which was filed with the court on May 15, 2015. In September 2015, the U.S. District Court for the District of Massachusetts approved the settlement, bringing the Consolidated Action challenging the Covidien transaction to a conclusion. Environmental Proceedings The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, Covidien filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. On April 3, 2014, the Maine Supreme Judicial Court affirmed the Maine Board’s compliance order. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and includes preliminary cost estimates for the potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million . The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. The Court intends to appoint an engineering firm to complete the further study work. The Company's accrued expenses for environmental proceedings are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Other Matters One of Covidien's subsidiaries, ev3 Inc., (ev3) acquired Appriva Medical, Inc. in 2002. The acquisition agreement relating to ev3’s acquisition of Appriva Medical contained four contingent milestone payments totaling $175 million . ev3 determined that the milestones were not achieved by the applicable dates and that none of the milestones were payable. On April 7, 2009, Michael Lesh and Erik Van Der Burg, acting jointly as the Shareholder Representatives for the former shareholders of Appriva Medical, filed a motion to amend their previously dismissed complaints in Superior Court of the State of Delaware. The plaintiffs asserted several claims, including breach of contract, fraudulent inducement and violation of California securities law. On May 1, 2013, the jury returned a verdict finding that ev3 breached the merger agreement and awarded $175 million in damages plus interest to the plaintiffs. On September 30, 2014, the Delaware Supreme Court reversed the jury’s verdict and remanded the case for a new trial. In October of 2015, the Company settled this matter for $ 65 million . The difference between the settlement amount and the $ 35 million previously accrued for this matter was recorded as an opening balance sheet adjustment related to the Covidien acquisition in the second quarter of fiscal year 2016. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. The Company continues to fully cooperate in connection with this matter. On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. The Company continues to fully cooperate in connection with this matter. On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company continues to fully cooperate in connection with this matter. The Company has not recorded an expense related to damages in connection with the issued subpoenas because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. Income Taxes In March 2009, the U.S. Internal Revenue Service (IRS) issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a Petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. The Company expects a ruling from the Tax Court sometime during fiscal year 2017. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. The significant issues that remain unresolved for these tax years relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the tax effects of its acquisition structures for Ardian, CoreValve, Inc., and Ablation Frontiers, Inc. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level; however, it will proceed through litigation, if necessary. The IRS continues to audit Medtronic, Inc.'s U.S. federal income tax returns for the fiscal years 2012 through 2014. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for the 2008 and 2009 tax years. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. Open periods for examination also include certain periods during which Covidien was a subsidiary of Tyco International plc (Tyco International). The resolution of these matters is subject to the conditions set forth in the Tyco tax sharing agreement. Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the 2007 separation. The IRS has concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for certain years after 2000. Tyco International has appealed certain of the tax adjustments proposed by the IRS and has resolved all but one of the matters associated with the proposed tax adjustments. With respect to the outstanding issue that remains in dispute, on June 20, 2013, Tyco International advised Covidien that it had received Notices of Deficiency from the IRS asserting that several of Tyco International’s former U.S. subsidiaries owe additional taxes of $914 million plus penalties of $154 million based on audits of the 1997 through 2000 tax years of Tyco International and its subsidiaries as they existed at that time. These amounts exclude interest and do not reflect the impact on subsequent periods if the IRS position is ultimately proved correct. The IRS has asserted in the Notices of Deficiency that substantially all of Tyco International’s intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International’s U.S. income tax returns totaling approximately $3.0 billion . The Company disagrees with the IRS’s proposed adjustments. On July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. The Company believes there are meritorious defenses for the tax filings in question, that the IRS positions with regard to these matters are inconsistent with the applicable tax laws and existing Treasury regulations, and that the previously reported taxes for the years in question are appropriate. No payments with respect to these matters or any additional matters that may be raised by the U.S. Tax Court would be required until the dispute is definitively resolved, which could take several years. The timing and outcome of such litigation is highly uncertain and could have a material adverse effect on the Company’s consolidated financial statements. In particular, if the IRS is successful in asserting its claim, it would likely assert that approximately $6.6 billion of interest deductions with respect to Tyco International’s intercompany debt in subsequent time periods should also be disallowed. Covidien’s income tax returns for the years 2001 through 2003 remain subject to adjustment by the IRS upon ultimate resolution of the disputed issue involving certain intercompany loans that originated during 1997 through 2000. Covidien and the IRS have effectively settled its audits of tax matters for the years 2004 through 2007. See Note 11 to the condensed consolidated financial statements for additional discussion of income taxes. Guarantees As a result of the recent acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity Ltd. (TE Connectivity), and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. On June 29, 2007, Covidien entered into a tax sharing agreement, under which Covidien shares responsibility for certain of its, Tyco International’s and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International and TE Connectivity share 42 percent , 27 percent , and 31 percent , respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to Covidien under the Tyco tax sharing agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the tax sharing agreement with Tyco International and TE Connectivity. Accordingly, Mallinckrodt does not share in Covidien’s liability to Tyco International and TE Connectivity, nor in the receivable that Covidien has from Tyco International and TE Connectivity. If any party to the Tyco tax sharing agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tyco tax sharing agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tyco tax sharing agreem

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Oct. 30, 2015
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment information The Company’s management evaluates performance and allocates resources based on profit and loss from operations before income taxes and interest expense, net, not including corporate determined charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . Net sales of the Company’s reportable segments include end-customer revenues from the sale of products they each develop and manufacture or distribute. Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Cardiac and Vascular Group $ 2,482 $ 2,286 $ 5,050 $ 4,540 Minimally Invasive Therapies Group 2,356 — 4,812 — Restorative Therapies Group 1,770 1,650 3,576 3,253 Diabetes Group 450 430 894 846 Total Net Sales $ 7,058 $ 4,366 $ 14,332 $ 8,639 Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Cardiac and Vascular Group $ 755 $ 714 $ 1,572 $ 1,426 Minimally Invasive Therapies Group 348 — 682 — Restorative Therapies Group 483 426 964 836 Diabetes Group 122 117 240 237 Total Reportable Segments’ Income Before Income Taxes 1,708 1,257 3,458 2,499 Special charges — (100 ) — (100 ) Impact of inventory step-up — — (226 ) — Restructuring charges, net (73 ) — (140 ) (30 ) Certain litigation charges (26 ) — (26 ) — Acquisition-related items (49 ) (61 ) (120 ) (102 ) Interest expense, net (217 ) (8 ) (408 ) (13 ) Corporate (260 ) (66 ) (515 ) (149 ) Total Income From Operations Before Income Taxes $ 1,083 $ 1,022 $ 2,023 $ 2,105 Geographic information Net sales to external customers by geography are as follows: Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Americas (b) $ 4,390 $ 2,643 $ 8,835 $ 5,133 EMEA (a) (c) 1,567 1,069 3,236 2,202 Asia-Pacific 736 433 1,506 866 Greater China 365 221 755 438 Total Net Sales $ 7,058 $ 4,366 $ 14,332 $ 8,639 (a) EMEA consists of the following regions: Europe, Middle East, and Africa. (b) The U.S., which is included in the Americas, had net sales to external customers of $4.098 billion and $8.240 billion for the three and six months ended October 30, 2015 , respectively, compared to $2.456 billion and $4.789 billion in the three and six months ended October 24, 2014 , respectively. (c) Sales within Ireland were insignificant during all periods presented. Certain prior period net sales to external customers by geography have been reclassified to conform to the current period classification.

Guarantor Financial Information

Guarantor Financial Information	6 Months Ended
	Oct. 30, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information On January 26, 2015, Medtronic plc (Parent Company Guarantor) and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a subsidiary guarantor, each provided a full and unconditional guarantee of the obligations of Medtronic, Inc. under the Senior Notes (Medtronic Senior Notes). In addition, Medtronic plc and Medtronic Luxco each provided a full and unconditional guarantee of the obligations of Covidien International Finance S.A. (CIFSA), assumed as part of the Covidien acquisition, under the Senior Notes (CIFSA Senior Notes). These guarantees of the CIFSA Senior Notes were in addition to the guarantees of the CIFSA Senior Notes by legacy Covidien holding companies Covidien Ltd. (f/k/a Covidien plc) and Covidien Group Holdings Ltd. (f/k/a Covidien Ltd.), both of which remain guarantors of the CIFSA Senior Notes. A summary of the guarantees is as follows: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Since Medtronic plc and Medtronic Luxco did not exist in the comparable period in the prior fiscal year, the Parent Company Guarantor column and Subsidiary Guarantor column in the consolidating financial information for the guarantee of the Medtronic Senior Notes will appear as zeros for the comparable period in fiscal year 2015. Accordingly, the consolidating financial information presented for the comparable period in the prior year is of the predecessor registrant, Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. There were no Medtronic plc or Medtronic Luxco guarantees in effect prior to the Acquisition Date, and the CIFSA Senior Notes were assumed as part of the Covidien acquisition. Therefore, no consolidating financial information for the period ended October 24, 2014 is presented related to the guarantee of the CIFSA Senior Notes. The following presents the Company’s Consolidating Statements of Comprehensive Income as of and for the three and six months ended October 30, 2015 and October 24, 2014 , and Condensed Consolidating Balance Sheets as of October 30, 2015 and April 24, 2015 , and Condensed Consolidating Statements of Cash Flows as of and for the six months ended October 30, 2015 . The guarantees provided by the Parent Company Guarantor and Subsidiary Guarantor(s) are joint and several. Condensed consolidating financial information for the Parent Company Guarantor, Subsidiary Issuer, and Subsidiary Guarantor(s), on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. The Company has made a revision to its condensed consolidating balance sheet of the guarantees of CIFSA Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 24, 2015. The $2.763 billion revision, in the line item Investment in Subsidiaries in the Subsidiary Issuer (CIFSA) column, occurred due to a $1.093 billion internal reorganization that took place during the second quarter of fiscal year 2016 and a $1.670 billion incorrect presentation primarily related to an intercompany dividend. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2015 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. Consolidating Statement of Comprehensive Income Three Months Ended October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 363 $ — $ 7,058 $ (363 ) $ 7,058 Costs and expenses: Cost of products sold — 345 — 2,393 (556 ) 2,182 Research and development expense — 85 — 440 20 545 Selling, general, and administrative expense 54 42 — 2,293 (46 ) 2,343 Restructuring charges, net — 5 — 68 — 73 Certain litigation charges — — — 26 — 26 Acquisition-related items — 55 — (6 ) — 49 Amortization of intangible assets — 3 — 480 — 483 Other (income) expense, net 56 (348 ) — 349 — 57 Operating profit (loss) (110 ) 176 — 1,015 219 1,300 Interest income — (57 ) (175 ) (116 ) 241 (107 ) Interest expense 4 455 3 103 (241 ) 324 Interest (income) expense, net 4 398 (172 ) (13 ) — 217 Equity in net (income) loss of subsidiaries (590 ) 5,902 (418 ) — (4,894 ) — Income (loss) from operations before income taxes 476 (6,124 ) 590 1,028 5,113 1,083 Provision (benefit) for income taxes (2 ) 3 — 562 — 563 Net income (loss) 478 (6,127 ) 590 466 5,113 520 Other comprehensive income (loss), net of tax (115 ) (52 ) (115 ) (195 ) 362 (115 ) Total comprehensive income (loss) $ 363 $ (6,179 ) $ 475 $ 271 $ 5,475 $ 405 Consolidating Statement of Comprehensive Income Six Months Ended October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 736 $ — $ 14,335 $ (739 ) $ 14,332 Costs and expenses: Cost of products sold — 700 — 4,604 (666 ) 4,638 Research and development expense — 219 — 864 20 1,103 Selling, general, and administrative expense 149 224 — 4,465 (46 ) 4,792 Restructuring charges, net — 5 — 135 — 140 Certain litigation charges — — — 26 — 26 Acquisition-related items — 55 — 65 — 120 Amortization of intangible assets — 6 — 958 — 964 Other (income) expense, net 34 (579 ) — 663 — 118 Operating profit (loss) (183 ) 106 — 2,555 (47 ) 2,431 Interest (income) — (121 ) (358 ) (229 ) 486 (222 ) Interest expense 5 899 3 209 (486 ) 630 Interest (income) expense, net 5 778 (355 ) (20 ) — 408 Equity in net (income) of subsidiaries (1,520 ) 4,947 (1,165 ) — (2,262 ) — Income (loss) from operations before income taxes 1,332 (5,619 ) 1,520 2,575 2,215 2,023 Provision (benefit) for income taxes (8 ) (159 ) — 850 — 683 Net income (loss) 1,340 (5,460 ) 1,520 1,725 2,215 1,340 Other comprehensive income (loss), net of tax (287 ) (224 ) (287 ) (367 ) 878 (287 ) Total comprehensive income $ 1,053 $ (5,684 ) $ 1,233 $ 1,358 $ 3,093 $ 1,053 Consolidating Statement of Comprehensive Income Three Months Ended October 24, 2014 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 309 $ — $ 4,375 $ (318 ) $ 4,366 Costs and expenses: Cost of products sold — 304 — 1,158 (320 ) 1,142 Research and development expense — 118 — 256 — 374 Selling, general, and administrative expense — 242 — 1,265 — 1,507 Special (gains) charges, net — 100 — — — 100 Restructuring charges, net — 6 — (6 ) — — Acquisition-related items — 98 — (37 ) — 61 Amortization of intangible assets — 3 — 86 — 89 Other (income) expense, net — (318 ) — 381 — 63 Operating profit (loss) — (244 ) — 1,272 2 1,030 Interest income — — — (86 ) — (86 ) Interest expense — 84 — 10 — 94 Interest (income) expense, net — 84 — (76 ) — 8 Equity in net (income) loss of subsidiaries — (1,033 ) — — 1,033 — Income from operations before income taxes — 705 — 1,348 (1,031 ) 1,022 Provision (benefit) for income taxes — (121 ) — 315 — 194 Net income — 826 — 1,033 (1,031 ) 828 Other comprehensive income, net of tax — (18 ) — (23 ) 23 (18 ) Total comprehensive income $ — $ 808 $ — $ 1,010 $ (1,008 ) $ 810 Consolidating Statement of Comprehensive Income Six Months Ended October 24, 2014 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 612 $ — $ 8,643 $ (616 ) $ 8,639 Costs and expenses: Cost of products sold — 602 — 2,261 (616 ) 2,247 Research and development expense — 234 — 505 — 739 Selling, general, and administrative expense — 483 — 2,530 — 3,013 Special (gains) charges, net — 100 — — — 100 Restructuring charges, net — 6 — 24 — 30 Acquisition-related items — 98 — 4 — 102 Amortization of intangible assets — 6 — 170 — 176 Other (income) expense, net — (533 ) — 647 — 114 Operating profit (loss) — (384 ) — 2,502 — 2,118 Interest income — — — (178 ) — (178 ) Interest expense — 173 — 18 — 191 Interest (income) expense, net — 173 — (160 ) — 13 Equity in net income of subsidiaries — (2,053 ) — — 2,053 — Income from operations before income taxes — 1,496 — 2,662 (2,053 ) 2,105 Provision (benefit) for income taxes — (203 ) — 609 — 406 Net income — 1,699 — 2,053 (2,053 ) 1,699 Other comprehensive income, net of tax — 91 — 86 (86 ) 91 Total comprehensive income $ — $ 1,790 $ — $ 2,139 $ (2,139 ) $ 1,790 Condensed Consolidating Balance Sheet October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 1 $ 285 $ 1 $ 2,091 $ — $ 2,378 Investments — 14 — 14,837 — 14,851 Accounts receivable, net — — — 5,044 — 5,044 Inventories — 170 — 3,580 (234 ) 3,516 Intercompany receivable 234 162,699 — 164,394 (327,327 ) — Tax assets — 376 — 1,243 — 1,619 Prepaid expenses and other current assets 2 115 — 1,198 — 1,315 Total current assets 237 163,659 1 192,387 (327,561 ) 28,723 Property, plant, and equipment, net — 1,026 — 3,652 — 4,678 Goodwill — 1,672 — 39,602 — 41,274 Other intangible assets, net — 36 — 27,695 — 27,731 Long-term tax assets — 535 — 290 — 825 Investment in subsidiaries 71,544 37,221 65,524 — (174,289 ) — Intercompany loans receivable 3,000 7,078 10,330 11,875 (32,283 ) — Other assets — 697 — 1,017 — 1,714 Total assets $ 74,781 $ 211,924 $ 75,855 $ 276,518 $ (534,133 ) $ 104,945 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 501 $ 1,307 $ 350 $ — $ 2,158 Accounts payable — 233 — 1,214 — 1,447 Intercompany payable 20,502 151,757 — 155,068 (327,327 ) — Accrued compensation 11 461 — 917 — 1,389 Accrued income taxes 13 — 1 519 — 533 Deferred tax liabilities — — — 142 — 142 Other accrued expenses 1 503 — 1,953 — 2,457 Total current liabilities 20,527 153,455 1,308 160,163 (327,327 ) 8,126 Long-term debt — 29,000 — 4,690 — 33,690 Long-term accrued compensation and retirement benefits — 996 — 581 — 1,577 Long-term accrued income taxes — 1,159 — 1,612 — 2,771 Long-term intercompany loans payable 1,985 10,221 10,000 10,077 (32,283 ) — Long-term deferred tax liabilities — — — 4,766 — 4,766 Other long-term liabilities — 234 — 1,512 — 1,746 Total liabilities 22,512 195,065 11,308 183,401 (359,610 ) 52,676 Shareholders’ equity 52,269 16,859 64,547 93,117 (174,523 ) 52,269 Total liabilities and shareholders’ equity $ 74,781 $ 211,924 $ 75,855 $ 276,518 $ (534,133 ) $ 104,945 Condensed Consolidating Balance Sheet April 24, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 1,071 $ 170 $ 3,339 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — 165 — 3,298 — 3,463 Intercompany receivable 259 146,373 — 150,679 (297,311 ) — Tax assets — 770 — 729 (164 ) 1,335 Prepaid expenses and other current assets 4 128 — 1,322 — 1,454 Total current assets 526 148,507 170 179,116 (297,475 ) 30,844 Property, plant, and equipment, net — 976 — 3,753 (30 ) 4,699 Goodwill — 1,607 — 38,923 — 40,530 Other intangible assets, net — 39 — 28,062 — 28,101 Long-term tax assets — 643 — 559 (428 ) 774 Investment in subsidiaries 70,255 42,311 64,335 — (176,901 ) — Intercompany loans receivable 3,000 6,516 10,000 10,218 (29,734 ) — Other assets — 678 — 1,059 — 1,737 Total assets $ 73,781 $ 201,277 $ 74,505 $ 261,690 $ (504,568 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,110 $ — $ 1,324 $ — $ 2,434 Accounts payable — 261 — 1,349 — 1,610 Intercompany payable 20,506 135,091 — 141,714 (297,311 ) — Accrued compensation 1 490 — 1,120 — 1,611 Accrued income taxes 41 371 — 523 — 935 Deferred tax liabilities 3 — — 280 (164 ) 119 Other accrued expenses — 600 — 1,894 (30 ) 2,464 Total current liabilities 20,551 137,923 — 148,204 (297,505 ) 9,173 Long-term debt — 29,004 — 4,748 — 33,752 Long-term accrued compensation and retirement benefits — 965 — 570 — 1,535 Long-term accrued income taxes — 1,450 — 1,026 — 2,476 Long-term intercompany loans payable — 10,218 10,000 9,516 (29,734 ) — Long-term deferred tax liabilities — — — 5,128 (428 ) 4,700 Other long-term liabilities — 207 — 1,612 — 1,819 Total liabilities 20,551 179,767 10,000 170,804 (327,667 ) 53,455 Shareholders’ equity 53,230 21,510 64,505 90,886 (176,901 ) 53,230 Total liabilities and shareholders’ equity $ 73,781 $ 201,277 $ 74,505 $ 261,690 $ (504,568 ) $ 106,685 Condensed Consolidating Statement of Cash Flows Six Months Ended October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (24 ) $ 454 $ (1,116 ) $ 2,781 $ — $ 2,095 Investing Activities: Acquisitions, net of cash acquired — — — (997 ) — (997 ) Additions to property, plant, and equipment — (129 ) — (317 ) — (446 ) Purchases of marketable securities — — — (3,370 ) — (3,370 ) Sales and maturities of marketable securities — — — 2,752 — 2,752 Net increase (decrease) in intercompany loans — (562 ) (330 ) (1,657 ) 2,549 — Other investing activities, net — — — (13 ) — (13 ) Net cash provided by (used in) investing activities — (691 ) (330 ) (3,602 ) 2,549 (2,074 ) Financing Activities: Acquisition-related contingent consideration — — — (19 ) — (19 ) Change in short-term borrowings, net — — 1,277 — — 1,277 Proceeds from short-term borrowings (maturities greater than 90 days) — 48 — — — 48 Payments on long-term debt — (600 ) — (1,008 ) — (1,608 ) Dividends to shareholders (1,075 ) — — — — (1,075 ) Issuance of ordinary shares 263 — — — — 263 Repurchase of ordinary shares (1,460 ) — — — — (1,460 ) Net intercompany loan borrowings (repayments) 1,985 3 — 561 (2,549 ) — Other financing activities 49 — — — — 49 Net cash provided by (used in) financing activities (238 ) (549 ) 1,277 (466 ) (2,549 ) (2,525 ) Effect of exchange rate changes on cash and cash equivalents — — — 39 — 39 Net change in cash and cash equivalents (262 ) (786 ) (169 ) (1,248 ) — (2,465 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ 1 $ 285 $ 1 $ 2,091 $ — $ 2,378 Condensed Consolidating Statement of Cash Flows Six Months Ended October 24, 2014 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by operating activities $ — $ 45 $ — $ 1,178 $ — $ 1,223 Investing Activities: Acquisitions, net of cash acquired — — — (578 ) — (578 ) Additions to property, plant, and equipment — (78 ) — (132 ) — (210 ) Purchases of marketable securities — — — (3,024 ) — (3,024 ) Sales and maturities of marketable securities — — — 2,665 — 2,665 Net decrease in intercompany loans — — — 23 (23 ) — Other investing activities, net — — — (6 ) — (6 ) Net cash used in investing activities — (78 ) — (1,052 ) (23 ) (1,153 ) Financing Activities: Acquisition-related contingent consideration — — — (5 ) — (5 ) Change in short-term borrowings, net — 1,611 — — — 1,611 Proceeds from short-term borrowings (maturities greater than 90 days) — 150 — — — 150 Payments on long-term debt — (7 ) — — — (7 ) Dividends to shareholders — (602 ) — — — (602 ) Issuance of ordinary shares — 312 — — — 312 Repurchase of ordinary shares — (1,620 ) — — — (1,620 ) Net intercompany loan borrowings (repayments) — (23 ) — — 23 — Other financing activities — 34 — — — 34 Net cash (used in) provided by financing activities — (145 ) — (5 ) 23 (127 ) Effect of exchange rate changes on cash and cash equivalents — — — (59 ) — (59 ) Net change in cash and cash equivalents — (178 ) — 62 — (116 ) Cash and cash equivalents at beginning of period — 264 — 1,139 — 1,403 Cash and cash equivalents at end of period $ — $ 86 $ — $ 1,201 $ — $ 1,287 Consolidating Statement of Comprehensive Income Three Months Ended October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,058 $ — $ 7,058 Costs and expenses: Cost of products sold — — — 2,156 26 2,182 Research and development expense — — — 525 20 545 Selling, general, and administrative expense 54 1 — 2,334 (46 ) 2,343 Restructuring charges, net — — — 73 — 73 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 49 — 49 Amortization of intangible assets — — — 483 — 483 Other (income) expense, net 56 — — 1 — 57 Operating profit (loss) (110 ) (1 ) — 1,411 — 1,300 Interest income — (150 ) (175 ) (115 ) 333 (107 ) Interest expense 4 27 3 623 (333 ) 324 Interest expense (income), net 4 (123 ) (172 ) 508 — 217 Equity in net (income) loss of subsidiaries (590 ) (7,292 ) (418 ) — 8,300 — Income from operations before income taxes 476 7,414 590 903 (8,300 ) 1,083 Provision (benefit) for income taxes (2 ) — — 565 — 563 Net income 478 7,414 590 338 (8,300 ) 520 Other comprehensive loss, net of tax (115 ) 109 (115 ) (115 ) 121 (115 ) Total comprehensive income (loss) $ 363 $ 7,523 $ 475 $ 223 $ (8,179 ) $ 405 Consolidating Statement of Comprehensive Income Six Months Ended October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 14,332 $ — $ 14,332 Costs and expenses: Cost of products sold — — — 4,612 26 4,638 Research and development expense — — — 1,083 20 1,103 Selling, general, and administrative expense 149 1 — 4,688 (46 ) 4,792 Restructuring charges, net — — — 140 — 140 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 120 — 120 Amortization of intangible assets — — — 964 — 964 Other (income) expense, net 34 — — 84 — 118 Operating profit (loss) (183 ) (1 ) — 2,615 — 2,431 Interest income — (310 ) (358 ) (230 ) 676 (222 ) Interest expense 5 59 3 1,239 (676 ) 630 Interest expense (income), net 5 (251 ) (355 ) 1,009 — 408 Equity in net (income) loss of subsidiaries (1,520 ) (7,262 ) (1,165 ) — 9,947 — Income from operations before income taxes 1,332 7,512 1,520 1,606 (9,947 ) 2,023 Provision (benefit) for income taxes (8 ) — — 691 — 683 Net income 1,340 7,512 1,520 915 (9,947 ) 1,340 Other comprehensive loss, net of tax (287 ) (63 ) (287 ) (287 ) 637 (287 ) Total comprehensive income (loss) $ 1,053 $ 7,449 $ 1,233 $ 628 $ (9,310 ) $ 1,053 Condensed Consolidating Balance Sheet October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 1 $ 140 $ 1 $ 2,236 $ — $ 2,378 Investments — — — 14,851 — 14,851 Accounts receivable, net — — — 5,044 — 5,044 Inventories — — — 3,516 — 3,516 Intercompany receivable 234 — 60 20,521 (20,815 ) — Tax assets — — — 1,619 — 1,619 Prepaid expenses and other current assets 2 — 5 1,308 — 1,315 Total current assets 237 140 66 49,095 (20,815 ) 28,723 Property, plant, and equipment, net — — — 4,678 — 4,678 Goodwill — — — 41,274 — 41,274 Other intangible assets, net — — — 27,731 — 27,731 Long-term tax assets — — — 825 — 825 Investment in subsidiaries 71,544 8,794 65,524 — (145,862 ) — Intercompany loans receivable 3,000 9,175 11,827 6,421 (30,423 ) — Other assets — — — 1,714 — 1,714 Total assets $ 74,781 $ 18,109 $ 77,417 $ 131,738 $ (197,100 ) $ 104,945 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ — $ 1,307 $ 851 $ — $ 2,158 Accounts payable — — — 1,447 — 1,447 Intercompany payable 20,502 — 288 25 (20,815 ) — Accrued compensation 11 — — 1,378 — 1,389 Accrued income taxes 13 — 1 519 — 533 Deferred tax liabilities — — — 142 — 142 Other accrued expenses 1 32 — 2,424 — 2,457 Total current liabilities 20,527 32 1,596 6,786 (20,815 ) 8,126 Long-term debt — 4,539 — 29,151 — 33,690 Long-term accrued compensation and retirement benefits — — — 1,577 — 1,577 Long-term accrued income taxes — — — 2,771 — 2,771 Long-term intercompany loans payable 1,985 7,918 10,000 10,520 (30,423 ) — Long-term deferred tax liabilities — — — 4,766 — 4,766 Other long-term liabilities — — — 1,746 — 1,746 Total liabilities 22,512 12,489 11,596 57,317 (51,238 ) 52,676 Shareholders’ equity 52,269 5,620 65,821 74,421 (145,862 ) 52,269 Total liabilities and shareholders’ equity $ 74,781 $ 18,109 $ 77,417 $ 131,738 $ (197,100 ) $ 104,945 Condensed Consolidating Balance Sheet April 24, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 728 $ 170 $ 3,682 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — — — 3,463 — 3,463 Intercompany receivable 259 — 269 20,508 (21,036 ) — Tax assets — — — 1,335 — 1,335 Prepaid expenses and other current assets 4 — 6 1,444 — 1,454 Total current assets 526 728 445 50,181 (21,036 ) 30,844 Property, plant, and equipment, net — — 1 4,728 (30 ) 4,699 Goodwill — — — 40,530 — 40,530 Other intangible assets, net — — — 28,101 — 28,101 Long-term tax assets — — — 774 — 774 Investment in subsidiaries 70,255 4,277 64,335 — (138,867 ) — Intercompany loans receivable 3,000 7,401 11,303 6,372 (28,076 ) — Other assets — — — 1,737 — 1,737 Total assets $ 73,781 $ 12,406 $ 76,084 $ 132,423 $ (188,009 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,002 $ — $ 1,432 $ — $ 2,434 Accounts payable — — 2 1,608 — 1,610 Intercompany payable 20,506 — 280 250 (21,036 ) — Accrued compensation 1 — — 1,610 — 1,611 Accrued income taxes 41 — — 894 — 935 Deferred tax liabilities 3 — — 116 — 119 Other accrued expenses — 40 1 2,453 (30 ) 2,464 Total current liabilities 20,551 1,042 283 8,363 (21,066 ) 9,173 Long-term debt — 4,580 — 29,172 — 33,752 Long-term accrued compensation and retirement benefits — — — 1,535 — 1,535 Long-term accrued income taxes — — — 2,476 — 2,476 Long-term intercompany loans payable — 8,385 10,002 9,689 (28,076 ) — Long-term deferred tax liabilities — — — 4,700 — 4,700 Other long-term liabilities — — — 1,819 — 1,819 Total liabilities 20,551 14,007 10,285 57,754 (49,142 ) 53,455 Shareholders’ equity 53,230 (1,601 ) 65,799 74,669 (138,867 ) 53,230 Total liabilities and shareholders’ equity $ 73,781 $ 12,406 $ 76,084 $ 132,423 $ (188,009 ) $ 106,685 Condensed Consolidating Statement of Cash Flows Six Months Ended October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (24 ) $ 2,605 $ (920 ) $ 2,984 $ (2,550 ) $ 2,095 Investing Activities: Acquisitions, net of cash acquired — — — (997 ) — (997 ) Additions to property, plant, and equipment — — — (446 ) — (446 ) Purchases of marketable securities — — — (3,370 ) — (3,370 ) Sales and maturities of marketable securities — — — 2,752 — 2,752 Net decrease in intercompany loans — (1,774 ) (524 ) (49 ) 2,347 — Other investing activities, net — — — (13 ) — (13 ) Net cash provided by (used in) investing activities — (1,774 ) (524 ) (2,123 ) 2,347 (2,074 ) Financing Activities: Acquisition-related contingent consideration — — — (19 ) — (19 ) Change in short-term borrowings, net — — 1,277 — — 1,277 Proceeds from short-term borrowings (maturities greater than 90 days) — 48 — — — 48 Payments on long-term debt — (1,000 ) — (608 ) — (1,608 ) Dividends to shareholders (1,075 ) — — — — (1,075 ) Issuance of ordinary shares 263 — — — — 263 Repurchase of ordinary shares (1,460 ) — — — — (1,460 ) Net intercompany loan borrowings (repayments) 1,985 (467 ) (2 ) 831 (2,347 ) — Intercompany dividend paid — — — (2,550 ) 2,550 — Other financing activities 49 — — — — 49 Net cash provided by (used in) financing activities (238 ) (1,419 ) 1,275 (2,346 ) 203 (2,525 ) Effect of exchange rate changes on cash and cash equivalents — — — 39 — 39 Net change in cash and cash equivalents (262 ) (588 ) (169 ) (1,446 ) — (2,465 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ 1 $ 140 $ 1 $ 2,236 $ — $ 2,378

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Oct. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Medtronic plc is the successor registrant to Medtronic, Inc. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended April 24, 2015 .
Fiscal Period	The Company’s fiscal years 2016 , 2015 , and 2014 will end or ended on April 29, 2016 , April 24, 2015 , and April 25, 2014 , respectively. Fiscal year 2016 is a 53-week year, and the extra week occurred during the first quarter.
New Accounting Pronouncements	Recently Adopted In April 2014, the Financial Accounting Standards Board (FASB) issued amended guidance for reporting discontinued operations. The amended guidance changes the criteria for determining when the results of operations are to be reported as discontinued operations and expands the related disclosure requirements. The guidance defines a discontinued operation as a component or group of components that is disposed of or classified as held for sale, which is a strategic shift that has, or will have, a major effect on financial position and results of operations. The Company prospectively adopted this accounting guidance in the first quarter of fiscal year 2016. Its adoption did not have a material impact on the Company's condensed consolidated financial statements. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s condensed consolidated financial statements.

Acquisitions and Acquisition-27

Acquisitions and Acquisition-Related Items (Tables)	6 Months Ended
	Oct. 30, 2015
Business Acquisition [Line Items]
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at ($ in millions) October 30, 2015 Valuation Technique Unobservable Input Range Discount rate 11% - 27.2% Revenue-based payments $203 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2016 - 2025 Discount rate 0.6% - 5.5% Product development-based payments $165 Discounted cash flow Probability of payment 15% - 100% Projected fiscal year of payment 2016 - 2020
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration associated with acquisitions subsequent to April 24, 2009: Three months ended Six months ended (in millions) October 30, 2015 October 24, 2014 October 30, 2015 October 24, 2014 Beginning Balance $ 291 $ 87 $ 264 $ 68 Purchase price contingent consideration 109 — 135 23 Contingent consideration payments (17 ) — (20 ) (5 ) Change in fair value of contingent consideration (15 ) 4 (11 ) 5 Ending Balance $ 368 $ 91 $ 368 $ 91
Covidien plc [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The preliminary fair values of the assets acquired and liabilities assumed in connection with the Transactions are as follows: (estimated in millions) January 26, 2015 (as previously reported) Adjustments January 26, 2015 (as adjusted) Accounts receivable $ 1,349 $ — $ 1,349 Inventories 2,222 (1 ) 2,221 Other current assets 2,949 185 3,134 Property, plant, and equipment 2,354 (21 ) 2,333 Goodwill 29,586 22 29,608 Intangible assets 26,265 (71 ) 26,194 Other assets 747 24 771 Total assets acquired 65,472 138 65,610 Short-term borrowings 1,011 — 1,011 Other current liabilities 2,331 87 2,418 Long-term debt 4,623 — 4,623 Long-term deferred tax liabilities 4,736 73 4,809 Other long-term liabilities 2,783 (22 ) 2,761 Total liabilities assumed 15,484 138 15,622 Net assets acquired $ 49,988 $ — $ 49,988
Acquisitions 2016 [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed during the six months ended October 30, 2015 are as follows: (in millions) Twelve, Inc. RF Surgical Systems, Inc. Medina Medical All Other Total Other current assets $ 60 $ 43 $ 11 $ 33 $ 147 Property, plant, and equipment — 3 — 4 7 IPR&D 192 — 122 108 422 Other intangible assets — 115 — 120 235 Goodwill 301 132 126 170 729 Other assets — 2 — 6 8 Total assets acquired 553 295 259 441 1,548 Current liabilities 37 28 6 17 88 Long-term deferred tax liabilities, net 44 27 34 29 134 Other liabilities — — — 2 2 Total liabilities assumed 81 55 40 48 224 Net assets acquired $ 472 $ 240 $ 219 $ 393 $ 1,324
Acquisitions 2015 [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed from acquisitions during fiscal year 2015, other than the Covidien acquisition, are as follows: (in millions) NGC Medical S.p.A. Sapiens Steering Brain Stimulation All Other Total Other current assets $ 55 $ 3 $ 12 $ 70 Property, plant, and equipment 15 1 2 18 IPR&D — 30 41 71 Other intangible assets 159 — 157 316 Goodwill 197 170 106 473 Other assets 3 3 49 55 Total assets acquired 429 207 367 1,003 Current liabilities 34 4 6 44 Long-term deferred tax liabilities, net 51 — 66 117 Other liabilities 4 — — 4 Total liabilities assumed 89 4 72 165 Net assets acquired $ 340 $ 203 $ 295 $ 838

Restructuring Charges, Net (Tab

Restructuring Charges, Net (Tables)	6 Months Ended
	Oct. 30, 2015
Cost Synergies Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the activity related to the cost synergies initiative is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total Balance as of April 24, 2015 $ 136 $ — $ 7 $ 143 Restructuring charges 52 — 15 67 Payments/write-downs (76 ) — (7 ) (83 ) Balance as of July 31, 2015 $ 112 $ — $ 15 $ 127 Restructuring charges 64 10 12 86 Payments/write-downs (28 ) (10 ) (6 ) (44 ) Reversal of excess accrual (13 ) — — (13 ) Balance as of October 30, 2015 $ 135 $ — $ 21 $ 156
Covidien Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the activity related to the Covidien initiative is presented below: (in millions) Employee Termination Costs Other Costs Total Balance as of April 24, 2015 $ 61 $ 17 $ 78 Payments (13 ) (5 ) (18 ) Balance as of July 31, 2015 $ 48 $ 12 $ 60 Payments (8 ) (6 ) (14 ) Balance as of October 30, 2015 $ 40 $ 6 $ 46

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Oct. 30, 2015
Investments [Abstract]
Investments by Category and Related Balance Sheet Presentation	The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at October 30, 2015 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities Level 1: U.S. government and agency securities $ 1,696 $ 7 $ (4 ) $ 1,699 $ 1,699 $ — Marketable equity securities 79 23 (3 ) 99 — 99 Total Level 1 1,775 30 (7 ) 1,798 1,699 99 Level 2: Corporate debt securities 6,618 50 (56 ) 6,612 6,612 — U.S. government and agency securities 1,537 3 (3 ) 1,537 1,537 — Mortgage-backed securities 1,466 14 (14 ) 1,466 1,466 — Foreign government and agency securities 65 — — 65 65 — Certificates of deposit 47 — — 47 47 — Other asset-backed securities 510 2 — 512 512 — Debt funds 3,148 6 (322 ) 2,832 2,832 — Total Level 2 13,391 75 (395 ) 13,071 13,071 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (7 ) 102 — 102 Total Level 3 110 — (7 ) 103 — 103 Total available-for-sale securities 15,276 105 (409 ) 14,972 14,770 202 Trading securities: Level 1: Exchange-traded funds 65 16 — 81 81 — Total Level 1: 65 16 — 81 81 — Total trading securities 65 16 — 81 81 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 484 — — N/A — 484 Total Level 3: 484 — — N/A — 484 Total cost method, equity method, and other investments 484 — — N/A — 484 Total investments $ 15,825 $ 121 $ (409 ) $ 15,053 $ 14,851 $ 686 The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at April 24, 2015 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 1,525 $ 17 $ (1 ) $ 1,541 $ 1,541 $ — Marketable equity securities 64 35 (19 ) 80 — 80 Total Level 1 1,589 52 (20 ) 1,621 1,541 80 Level 2: Corporate debt securities 6,282 105 (10 ) 6,377 6,377 — U.S. government and agency securities 1,597 4 (3 ) 1,598 1,598 — Mortgage-backed securities 1,462 22 (6 ) 1,478 1,478 — Foreign government and agency securities 85 — — 85 85 — Certificates of deposit 44 — — 44 44 — Other asset-backed securities 504 3 — 507 507 — Debt funds 3,061 19 (150 ) 2,930 2,930 — Total Level 2 13,035 153 (169 ) 13,019 13,019 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (4 ) 105 — 105 Total Level 3 110 — (4 ) 106 — 106 Total available-for-sale securities 14,734 205 (193 ) 14,746 14,560 186 Trading securities: Level 1: Exchange-traded funds 58 19 — 77 77 — Total Level 1 58 19 — 77 77 — Total trading securities 58 19 — 77 77 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 520 — — N/A — 520 Total Level 3 520 — — N/A — 520 Total cost method, equity method, and other investments 520 — — N/A — 520 Total investments $ 15,312 $ 224 $ (193 ) $ 14,823 $ 14,637 $ 706
Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category	The following tables show the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category as of October 30, 2015 and April 24, 2015 : October 30, 2015 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 2,932 $ (50 ) $ 183 $ (6 ) Auction rate securities — — 102 (7 ) Mortgage-backed securities 622 (10 ) 225 (4 ) U.S. government and agency securities 1,146 (5 ) 142 (2 ) Debt funds 1,190 (93 ) 1,128 (229 ) Marketable equity securities 26 (3 ) — — Total $ 5,916 $ (161 ) $ 1,780 $ (248 ) April 24, 2015 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 944 $ (9 ) $ 34 $ (1 ) Auction rate securities — — 105 (4 ) Mortgage-backed securities 346 (3 ) 206 (3 ) U.S. government and agency securities 356 (1 ) 267 (3 ) Debt funds 1,291 (109 ) 559 (41 ) Marketable equity securities 4 (19 ) — — Total $ 2,941 $ (141 ) $ 1,171 $ (52 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 as of October 30, 2015 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6%
Reconciliation of Beginning and Ending Balances of Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3)	The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended October 30, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of July 31, 2015 $ 103 $ 1 $ 102 Total unrealized gains included in other comprehensive income — — — Balance as of October 30, 2015 $ 103 $ 1 $ 102 Three months ended October 24, 2014 (in millions) Total Level 3 Corporate debt Auction rate Balance as of July 25, 2014 $ 108 $ 9 $ 99 Total unrealized gains included in other comprehensive income — — — Balance as of October 24, 2014 $ 108 $ 9 $ 99 Six months ended October 30, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2015 $ 106 $ 1 $ 105 Total unrealized losses included in other comprehensive income (3 ) — (3 ) Balance as of October 30, 2015 $ 103 $ 1 $ 102 Six months ended October 24, 2014 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2014 $ 106 $ 9 $ 97 Total unrealized gains included in other comprehensive income 2 — 2 Balance as of October 24, 2014 $ 108 $ 9 $ 99
Activity Related to the Company's Investment Portfolio	Activity related to the Company’s investment portfolio is as follows: Three months ended October 30, 2015 October 24, 2014 (in millions) Debt (a) Equity (b) (c) Debt (a) Equity (b) (d) Proceeds from sales $ 1,481 $ 5 $ 806 $ 7 Gross realized gains 4 20 4 39 Gross realized losses (7 ) — (2 ) — Impairment losses recognized — (19 ) — (20 ) Six months ended October 30, 2015 October 24, 2014 (in millions) Debt (a) Equity (b) (c) Debt (a) Equity (b) (e) Proceeds from sales $ 2,718 $ 34 $ 2,636 $ 29 Gross realized gains 9 32 16 58 Gross realized losses (12 ) — (5 ) — Impairment losses recognized — (42 ) — (20 ) (a) Includes available-for-sale debt securities. (b) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments. (c) As a result of certain acquisitions that occurred during the three and six months ended October 30, 2015 , the Company recognized a non-cash realized gain of $9 million on its previously-held minority investment included in other expense, net on the condensed consolidated statement of income. (d) As a result of certain acquisitions that occurred during the three months ended October 24, 2014 , the Company recognized a non-cash realized gain of $35 million on its previously-held minority investment included in other expense, net on the condensed consolidated statement of income. (e) As a result of certain acquisitions that occurred during the six months ended October 24, 2014 , the Company recognized a non-cash realized gain of $41 million on its previously-held minority investments included in other expense, net on the condensed consolidated statement of income.
Available-for-sale Debt Securities Contractual Maturities	The October 30, 2015 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) October 30, 2015 Due in one year or less $ 2,245 Due after one year through five years 6,314 Due after five years through ten years 3,197 Due after ten years 285 Total $ 12,041

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Oct. 30, 2015
Debt Disclosure [Abstract]
Long-term Debt	Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year Payable as of October 30, 2015 Payable as of April 24, 2015 Floating rate three-year 2014 senior notes 2017 $ 250 $ 250 0.875 percent three-year 2014 senior notes 2017 250 250 6.000 percent ten-year 2008 CIFSA senior notes 2018 1,150 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 1,250 1,250 4.200 percent ten-year 2010 CIFSA senior notes 2020 600 600 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.200 percent ten-year 2012 CIFSA senior notes 2022 650 650 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 2.750 percent ten-year 2013 senior notes 2023 1,250 1,250 2.950 percent ten-year 2013 CIFSA senior notes 2023 750 750 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,500 2,500 6.550 percent thirty-year 2007 CIFSA senior notes 2037 850 850 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 750 750 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 3,000 3,000 Interest rate swaps (Note 8) 2017 - 2022 72 79 Deferred gains from interest rate swap terminations, net - — 3 Capital lease obligations 2017 - 2025 121 129 Bank borrowings 2021 32 17 Debt premium 2017 - 2045 440 499 Total Long-Term Debt $ 33,690 $ 33,752

Derivatives and Foreign Excha31

Derivatives and Foreign Exchange Risk Management (Tables)	6 Months Ended
	Oct. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amount and location of the gains (losses) in the condensed consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and six months ended October 30, 2015 and October 24, 2014 are as follows: (in millions) Three months ended Derivatives Not Designated as Hedging Instruments Location October 30, 2015 October 24, 2014 Foreign currency exchange rate contracts gains (losses) Other expense, net $ (4 ) $ 73 (in millions) Six months ended Derivatives Not Designated as Hedging Instruments Location October 30, 2015 October 24, 2014 Foreign currency exchange rate contracts gains (losses) Other expense, net $ 16 $ 49
Amount and Location of Gains (Losses) in Statements of Income and OCI, Derivative Instruments Designated as Cash Flow Hedges	The amount of gains (losses) and location of the gains (losses) in the condensed consolidated statements of income and other comprehensive income (OCI) related to foreign currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended October 30, 2015 and October 24, 2014 are as follows: Three months ended October 30, 2015 Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 17 Other expense, net $ 89 Cost of products sold (15 ) Total $ 17 $ 74 Three months ended October 24, 2014 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 229 Other expense, net $ 20 Cost of products sold 1 Total $ 229 $ 21 Six months ended October 30, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 3 Other expense, net $ 184 Cost of products sold (36 ) Total $ 3 $ 148 Six months ended October 24, 2014 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 291 Other expense, net $ 21 Cost of products sold (2 ) Total $ 291 $ 19
Location and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets as of October 30, 2015 and April 24, 2015 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. October 30, 2015 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 2 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 286 Other accrued expenses 18 Interest rate contracts Other assets 72 Other long-term liabilities 72 Foreign currency exchange rate contracts Other assets 89 Other long-term liabilities 5 Total derivatives designated as hedging instruments $ 449 $ 95 Derivatives not designated as hedging instruments Commodity derivatives Prepaid expenses and $ — Other accrued expenses $ 9 Foreign currency exchange rate contracts Prepaid expenses and other current assets 28 Other accrued expenses 24 Cross currency interest rate contracts Other assets 21 Other long-term liabilities 4 Total derivatives not designated as hedging instruments $ 49 $ 37 Total derivatives $ 498 $ 132 April 24, 2015 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 10 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 382 Other accrued expenses 12 Interest rate contracts Other assets 79 Other long-term liabilities 71 Foreign currency exchange rate contracts Other assets 143 Other long-term liabilities 3 Total derivatives designated as hedging instruments $ 614 $ 86 Derivatives not designated as hedging instruments Foreign currency exchange rate contracts Prepaid expenses and other current assets $ 119 Other accrued expenses $ 30 Total derivatives not designated as hedging instruments $ 119 $ 30 Total derivatives $ 733 $ 116
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis as of October 30, 2015 and April 24, 2015: (in millions) October 30, 2015 April 24, 2015 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative Assets $ 403 $ 95 $ — $ 644 $ 89 $ — Derivative Liabilities 47 85 — 45 71 —
Offsetting Assets	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 30, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 403 $ (66 ) $ (205 ) $ 132 Interest rate contracts 74 (8 ) (12 ) 54 Cross currency interest rate contracts 21 — — 21 $ 498 $ (74 ) $ (217 ) $ 207 Derivative Liabilities Foreign currency exchange rate contracts $ (47 ) $ 39 $ — $ (8 ) Interest rate contracts (72 ) 35 16 (21 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity derivatives (9 ) — — (9 ) $ (132 ) $ 74 $ 16 $ (42 ) Total $ 366 $ — $ (201 ) $ 165 April 24, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 644 $ (61 ) $ (325 ) $ 258 Interest rate contracts 89 (10 ) (13 ) 66 $ 733 $ (71 ) $ (338 ) $ 324 Derivative Liabilities Foreign currency exchange rate contracts $ (45 ) $ 31 $ — $ (14 ) Interest rate contracts (71 ) 40 8 (23 ) $ (116 ) $ 71 $ 8 $ (37 ) Total $ 617 $ — $ (330 ) $ 287
Offsetting Liabilities	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 30, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 403 $ (66 ) $ (205 ) $ 132 Interest rate contracts 74 (8 ) (12 ) 54 Cross currency interest rate contracts 21 — — 21 $ 498 $ (74 ) $ (217 ) $ 207 Derivative Liabilities Foreign currency exchange rate contracts $ (47 ) $ 39 $ — $ (8 ) Interest rate contracts (72 ) 35 16 (21 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity derivatives (9 ) — — (9 ) $ (132 ) $ 74 $ 16 $ (42 ) Total $ 366 $ — $ (201 ) $ 165 April 24, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 644 $ (61 ) $ (325 ) $ 258 Interest rate contracts 89 (10 ) (13 ) 66 $ 733 $ (71 ) $ (338 ) $ 324 Derivative Liabilities Foreign currency exchange rate contracts $ (45 ) $ 31 $ — $ (14 ) Interest rate contracts (71 ) 40 8 (23 ) $ (116 ) $ 71 $ 8 $ (37 ) Total $ 617 $ — $ (330 ) $ 287

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Oct. 30, 2015
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances were as follows: (in millions) October 30, 2015 April 24, 2015 Finished goods $ 2,244 $ 2,268 Work in-process 527 509 Raw materials 745 686 Total $ 3,516 $ 3,463

Goodwill and Other Intangible33

Goodwill and Other Intangible Assets, Net (Tables)	6 Months Ended
	Oct. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the six months ended October 30, 2015 are as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total Balance as of April 24, 2015 $ 5,855 $ 23,399 $ 9,424 $ 1,852 $ 40,530 Goodwill as a result of acquisitions 409 132 191 — 732 Purchase accounting adjustments, net 24 (9 ) 5 — 20 Currency adjustment, net (6 ) — (3 ) 1 (8 ) Balance as of October 30, 2015 $ 6,282 $ 23,522 $ 9,617 $ 1,853 $ 41,274
Gross Carrying Amount of Non-Amortizable Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at October 30, 2015 and April 24, 2015 are as follows: October 30, 2015 April 24, 2015 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Customer-related $ 18,579 $ (801 ) $ 18,492 $ (273 ) Purchased technology and patents 11,265 (2,560 ) 11,118 (2,268 ) Trademarks and tradenames 850 (408 ) 640 (363 ) Other 84 (47 ) 79 (44 ) Total $ 30,778 $ (3,816 ) $ 30,329 $ (2,948 ) Non-Amortizable: IPR&D $ 769 $ 470 Tradenames — 250 Total $ 769 $ 720
Gross Carrying Amount and Accumulated Amortization of Amortizable Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at October 30, 2015 and April 24, 2015 are as follows: October 30, 2015 April 24, 2015 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Customer-related $ 18,579 $ (801 ) $ 18,492 $ (273 ) Purchased technology and patents 11,265 (2,560 ) 11,118 (2,268 ) Trademarks and tradenames 850 (408 ) 640 (363 ) Other 84 (47 ) 79 (44 ) Total $ 30,778 $ (3,816 ) $ 30,329 $ (2,948 ) Non-Amortizable: IPR&D $ 769 $ 470 Tradenames — 250 Total $ 769 $ 720
Estimated Future Aggregate Amortization Expense, Amortizable Intangible Assets	Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets as of October 30, 2015 , excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows: (in millions) Fiscal Year Estimated Amortization Expense Remaining 2016 $ 964 2017 1,913 2018 1,882 2019 1,789 2020 1,741 2021 1,724

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Oct. 30, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended Six months ended (in millions, except per share data) October 30, October 24, October 30, October 24, Numerator: Net income attributable to ordinary shareholders $ 520 $ 828 $ 1,340 $ 1,699 Denominator: Basic – weighted average shares outstanding 1,412.9 981.9 1,415.6 987.5 Effect of dilutive securities: Employee stock options 12.2 7.3 12.7 7.4 Employee restricted stock units 3.6 3.7 4.3 4.4 Other 0.1 0.1 0.1 0.1 Diluted – weighted average shares outstanding 1,428.8 993.0 1,432.7 999.4 Basic earnings per share $ 0.37 $ 0.84 $ 0.95 $ 1.72 Diluted earnings per share $ 0.36 $ 0.83 $ 0.94 $ 1.70

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Oct. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense recognized for the three and six months ended October 30, 2015 and October 24, 2014 : Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Stock options $ 62 $ 14 $ 119 $ 20 Restricted stock awards 46 31 80 54 Employee stock purchase plan 5 3 10 8 Total stock-based compensation expense $ 113 $ 48 $ 209 $ 82 Cost of products sold $ 14 $ 4 $ 26 $ 8 Research and development expense 12 9 20 15 Selling, general, and administrative expense 65 35 114 59 Restructuring charges, net 6 — 14 — Acquisition-related items 16 — 35 — Total stock-based compensation expense $ 113 $ 48 $ 209 $ 82 Income tax benefits (34 ) (14 ) (63 ) (23 ) Total stock-based compensation expense, net of tax $ 79 $ 34 $ 146 $ 59

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	6 Months Ended
	Oct. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 30, 2015 and October 24, 2014 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) October 30, October 24, October 30, October 24, Service cost $ 30 $ 26 $ 22 $ 15 Interest cost 31 26 9 8 Expected return on plan assets (45 ) (39 ) (13 ) (10 ) Amortization of net actuarial loss 24 16 6 3 Net periodic benefit cost $ 40 $ 29 $ 24 $ 16 U.S. Pension Benefits Non-U.S. Pension Benefits Six months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Service cost $ 60 $ 52 $ 44 $ 30 Interest cost 62 52 18 16 Expected return on plan assets (90 ) (78 ) (26 ) (20 ) Amortization of net actuarial loss 48 32 12 6 Net periodic benefit cost $ 80 $ 58 $ 48 $ 32

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Oct. 30, 2015
Equity [Abstract]
Changes in AOCI by Component	Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (302 ) (59 ) (5 ) 44 (322 ) Tax benefit (expense) 108 — — (17 ) 91 Other comprehensive (loss) income before reclassifications, net of tax (194 ) (59 ) (5 ) 27 (231 ) Reclassifications, before tax (20 ) — 60 (133 ) (93 ) Tax benefit (expense) 7 — (20 ) 50 37 Reclassifications, net of tax (13 ) (b) — 40 (c) (83 ) (d) (56 ) Other comprehensive (loss) income, net of tax (207 ) (59 ) 35 (56 ) (287 ) Balance as of October 30, 2015, net of tax $ (193 ) $ (336 ) $ (1,096 ) $ 154 $ (1,471 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 25, 2014, net of tax $ (6 ) $ 218 $ (765 ) $ (44 ) $ (597 ) Other comprehensive income (loss) before reclassifications, before tax 61 (129 ) 16 263 211 Tax expense (22 ) — — (93 ) (115 ) Other comprehensive income before reclassifications, net of tax 39 (129 ) 16 170 96 Reclassifications, before tax (28 ) — 38 (16 ) (6 ) Tax benefit (expense) 9 — (12 ) 4 1 Reclassifications, net of tax (19 ) (b) — 26 (c) (12 ) (d) (5 ) Other comprehensive income (loss), net of tax 20 (129 ) 42 158 91 Balance as of October 24, 2014, net of tax $ 14 $ 89 $ (723 ) $ 114 $ (506 ) (a) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (b) Represents net realized gains on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 6 ). (c) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 14 ). (d) Relates to foreign currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 8 ).

Segment and Geographic Inform38

Segment and Geographic Information (Tables)	6 Months Ended
	Oct. 30, 2015
Segment Reporting [Abstract]
Net Sales by Segment	Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Cardiac and Vascular Group $ 2,482 $ 2,286 $ 5,050 $ 4,540 Minimally Invasive Therapies Group 2,356 — 4,812 — Restorative Therapies Group 1,770 1,650 3,576 3,253 Diabetes Group 450 430 894 846 Total Net Sales $ 7,058 $ 4,366 $ 14,332 $ 8,639
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Cardiac and Vascular Group $ 755 $ 714 $ 1,572 $ 1,426 Minimally Invasive Therapies Group 348 — 682 — Restorative Therapies Group 483 426 964 836 Diabetes Group 122 117 240 237 Total Reportable Segments’ Income Before Income Taxes 1,708 1,257 3,458 2,499 Special charges — (100 ) — (100 ) Impact of inventory step-up — — (226 ) — Restructuring charges, net (73 ) — (140 ) (30 ) Certain litigation charges (26 ) — (26 ) — Acquisition-related items (49 ) (61 ) (120 ) (102 ) Interest expense, net (217 ) (8 ) (408 ) (13 ) Corporate (260 ) (66 ) (515 ) (149 ) Total Income From Operations Before Income Taxes $ 1,083 $ 1,022 $ 2,023 $ 2,105
Net Sales to External Customers by Geography	Net sales to external customers by geography are as follows: Three months ended Six months ended (in millions) October 30, October 24, October 30, October 24, Americas (b) $ 4,390 $ 2,643 $ 8,835 $ 5,133 EMEA (a) (c) 1,567 1,069 3,236 2,202 Asia-Pacific 736 433 1,506 866 Greater China 365 221 755 438 Total Net Sales $ 7,058 $ 4,366 $ 14,332 $ 8,639 (a) EMEA consists of the following regions: Europe, Middle East, and Africa. (b) The U.S., which is included in the Americas, had net sales to external customers of $4.098 billion and $8.240 billion for the three and six months ended October 30, 2015 , respectively, compared to $2.456 billion and $4.789 billion in the three and six months ended October 24, 2014 , respectively. (c) Sales within Ireland were insignificant during all periods presented.

Guarantor Financial Informati39

Guarantor Financial Information (Tables)	6 Months Ended
	Oct. 30, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 363 $ — $ 7,058 $ (363 ) $ 7,058 Costs and expenses: Cost of products sold — 345 — 2,393 (556 ) 2,182 Research and development expense — 85 — 440 20 545 Selling, general, and administrative expense 54 42 — 2,293 (46 ) 2,343 Restructuring charges, net — 5 — 68 — 73 Certain litigation charges — — — 26 — 26 Acquisition-related items — 55 — (6 ) — 49 Amortization of intangible assets — 3 — 480 — 483 Other (income) expense, net 56 (348 ) — 349 — 57 Operating profit (loss) (110 ) 176 — 1,015 219 1,300 Interest income — (57 ) (175 ) (116 ) 241 (107 ) Interest expense 4 455 3 103 (241 ) 324 Interest (income) expense, net 4 398 (172 ) (13 ) — 217 Equity in net (income) loss of subsidiaries (590 ) 5,902 (418 ) — (4,894 ) — Income (loss) from operations before income taxes 476 (6,124 ) 590 1,028 5,113 1,083 Provision (benefit) for income taxes (2 ) 3 — 562 — 563 Net income (loss) 478 (6,127 ) 590 466 5,113 520 Other comprehensive income (loss), net of tax (115 ) (52 ) (115 ) (195 ) 362 (115 ) Total comprehensive income (loss) $ 363 $ (6,179 ) $ 475 $ 271 $ 5,475 $ 405 Consolidating Statement of Comprehensive Income Six Months Ended October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 736 $ — $ 14,335 $ (739 ) $ 14,332 Costs and expenses: Cost of products sold — 700 — 4,604 (666 ) 4,638 Research and development expense — 219 — 864 20 1,103 Selling, general, and administrative expense 149 224 — 4,465 (46 ) 4,792 Restructuring charges, net — 5 — 135 — 140 Certain litigation charges — — — 26 — 26 Acquisition-related items — 55 — 65 — 120 Amortization of intangible assets — 6 — 958 — 964 Other (income) expense, net 34 (579 ) — 663 — 118 Operating profit (loss) (183 ) 106 — 2,555 (47 ) 2,431 Interest (income) — (121 ) (358 ) (229 ) 486 (222 ) Interest expense 5 899 3 209 (486 ) 630 Interest (income) expense, net 5 778 (355 ) (20 ) — 408 Equity in net (income) of subsidiaries (1,520 ) 4,947 (1,165 ) — (2,262 ) — Income (loss) from operations before income taxes 1,332 (5,619 ) 1,520 2,575 2,215 2,023 Provision (benefit) for income taxes (8 ) (159 ) — 850 — 683 Net income (loss) 1,340 (5,460 ) 1,520 1,725 2,215 1,340 Other comprehensive income (loss), net of tax (287 ) (224 ) (287 ) (367 ) 878 (287 ) Total comprehensive income $ 1,053 $ (5,684 ) $ 1,233 $ 1,358 $ 3,093 $ 1,053 Consolidating Statement of Comprehensive Income Three Months Ended October 24, 2014 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 309 $ — $ 4,375 $ (318 ) $ 4,366 Costs and expenses: Cost of products sold — 304 — 1,158 (320 ) 1,142 Research and development expense — 118 — 256 — 374 Selling, general, and administrative expense — 242 — 1,265 — 1,507 Special (gains) charges, net — 100 — — — 100 Restructuring charges, net — 6 — (6 ) — — Acquisition-related items — 98 — (37 ) — 61 Amortization of intangible assets — 3 — 86 — 89 Other (income) expense, net — (318 ) — 381 — 63 Operating profit (loss) — (244 ) — 1,272 2 1,030 Interest income — — — (86 ) — (86 ) Interest expense — 84 — 10 — 94 Interest (income) expense, net — 84 — (76 ) — 8 Equity in net (income) loss of subsidiaries — (1,033 ) — — 1,033 — Income from operations before income taxes — 705 — 1,348 (1,031 ) 1,022 Provision (benefit) for income taxes — (121 ) — 315 — 194 Net income — 826 — 1,033 (1,031 ) 828 Other comprehensive income, net of tax — (18 ) — (23 ) 23 (18 ) Total comprehensive income $ — $ 808 $ — $ 1,010 $ (1,008 ) $ 810 Consolidating Statement of Comprehensive Income Six Months Ended October 24, 2014 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 612 $ — $ 8,643 $ (616 ) $ 8,639 Costs and expenses: Cost of products sold — 602 — 2,261 (616 ) 2,247 Research and development expense — 234 — 505 — 739 Selling, general, and administrative expense — 483 — 2,530 — 3,013 Special (gains) charges, net — 100 — — — 100 Restructuring charges, net — 6 — 24 — 30 Acquisition-related items — 98 — 4 — 102 Amortization of intangible assets — 6 — 170 — 176 Other (income) expense, net — (533 ) — 647 — 114 Operating profit (loss) — (384 ) — 2,502 — 2,118 Interest income — — — (178 ) — (178 ) Interest expense — 173 — 18 — 191 Interest (income) expense, net — 173 — (160 ) — 13 Equity in net income of subsidiaries — (2,053 ) — — 2,053 — Income from operations before income taxes — 1,496 — 2,662 (2,053 ) 2,105 Provision (benefit) for income taxes — (203 ) — 609 — 406 Net income — 1,699 — 2,053 (2,053 ) 1,699 Other comprehensive income, net of tax — 91 — 86 (86 ) 91 Total comprehensive income $ — $ 1,790 $ — $ 2,139 $ (2,139 ) $ 1,790 Consolidating Statement of Comprehensive Income Three Months Ended October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,058 $ — $ 7,058 Costs and expenses: Cost of products sold — — — 2,156 26 2,182 Research and development expense — — — 525 20 545 Selling, general, and administrative expense 54 1 — 2,334 (46 ) 2,343 Restructuring charges, net — — — 73 — 73 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 49 — 49 Amortization of intangible assets — — — 483 — 483 Other (income) expense, net 56 — — 1 — 57 Operating profit (loss) (110 ) (1 ) — 1,411 — 1,300 Interest income — (150 ) (175 ) (115 ) 333 (107 ) Interest expense 4 27 3 623 (333 ) 324 Interest expense (income), net 4 (123 ) (172 ) 508 — 217 Equity in net (income) loss of subsidiaries (590 ) (7,292 ) (418 ) — 8,300 — Income from operations before income taxes 476 7,414 590 903 (8,300 ) 1,083 Provision (benefit) for income taxes (2 ) — — 565 — 563 Net income 478 7,414 590 338 (8,300 ) 520 Other comprehensive loss, net of tax (115 ) 109 (115 ) (115 ) 121 (115 ) Total comprehensive income (loss) $ 363 $ 7,523 $ 475 $ 223 $ (8,179 ) $ 405 Consolidating Statement of Comprehensive Income Six Months Ended October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 14,332 $ — $ 14,332 Costs and expenses: Cost of products sold — — — 4,612 26 4,638 Research and development expense — — — 1,083 20 1,103 Selling, general, and administrative expense 149 1 — 4,688 (46 ) 4,792 Restructuring charges, net — — — 140 — 140 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 120 — 120 Amortization of intangible assets — — — 964 — 964 Other (income) expense, net 34 — — 84 — 118 Operating profit (loss) (183 ) (1 ) — 2,615 — 2,431 Interest income — (310 ) (358 ) (230 ) 676 (222 ) Interest expense 5 59 3 1,239 (676 ) 630 Interest expense (income), net 5 (251 ) (355 ) 1,009 — 408 Equity in net (income) loss of subsidiaries (1,520 ) (7,262 ) (1,165 ) — 9,947 — Income from operations before income taxes 1,332 7,512 1,520 1,606 (9,947 ) 2,023 Provision (benefit) for income taxes (8 ) — — 691 — 683 Net income 1,340 7,512 1,520 915 (9,947 ) 1,340 Other comprehensive loss, net of tax (287 ) (63 ) (287 ) (287 ) 637 (287 ) Total comprehensive income (loss) $ 1,053 $ 7,449 $ 1,233 $ 628 $ (9,310 ) $ 1,053
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 1 $ 285 $ 1 $ 2,091 $ — $ 2,378 Investments — 14 — 14,837 — 14,851 Accounts receivable, net — — — 5,044 — 5,044 Inventories — 170 — 3,580 (234 ) 3,516 Intercompany receivable 234 162,699 — 164,394 (327,327 ) — Tax assets — 376 — 1,243 — 1,619 Prepaid expenses and other current assets 2 115 — 1,198 — 1,315 Total current assets 237 163,659 1 192,387 (327,561 ) 28,723 Property, plant, and equipment, net — 1,026 — 3,652 — 4,678 Goodwill — 1,672 — 39,602 — 41,274 Other intangible assets, net — 36 — 27,695 — 27,731 Long-term tax assets — 535 — 290 — 825 Investment in subsidiaries 71,544 37,221 65,524 — (174,289 ) — Intercompany loans receivable 3,000 7,078 10,330 11,875 (32,283 ) — Other assets — 697 — 1,017 — 1,714 Total assets $ 74,781 $ 211,924 $ 75,855 $ 276,518 $ (534,133 ) $ 104,945 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 501 $ 1,307 $ 350 $ — $ 2,158 Accounts payable — 233 — 1,214 — 1,447 Intercompany payable 20,502 151,757 — 155,068 (327,327 ) — Accrued compensation 11 461 — 917 — 1,389 Accrued income taxes 13 — 1 519 — 533 Deferred tax liabilities — — — 142 — 142 Other accrued expenses 1 503 — 1,953 — 2,457 Total current liabilities 20,527 153,455 1,308 160,163 (327,327 ) 8,126 Long-term debt — 29,000 — 4,690 — 33,690 Long-term accrued compensation and retirement benefits — 996 — 581 — 1,577 Long-term accrued income taxes — 1,159 — 1,612 — 2,771 Long-term intercompany loans payable 1,985 10,221 10,000 10,077 (32,283 ) — Long-term deferred tax liabilities — — — 4,766 — 4,766 Other long-term liabilities — 234 — 1,512 — 1,746 Total liabilities 22,512 195,065 11,308 183,401 (359,610 ) 52,676 Shareholders’ equity 52,269 16,859 64,547 93,117 (174,523 ) 52,269 Total liabilities and shareholders’ equity $ 74,781 $ 211,924 $ 75,855 $ 276,518 $ (534,133 ) $ 104,945 Condensed Consolidating Balance Sheet April 24, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 1,071 $ 170 $ 3,339 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — 165 — 3,298 — 3,463 Intercompany receivable 259 146,373 — 150,679 (297,311 ) — Tax assets — 770 — 729 (164 ) 1,335 Prepaid expenses and other current assets 4 128 — 1,322 — 1,454 Total current assets 526 148,507 170 179,116 (297,475 ) 30,844 Property, plant, and equipment, net — 976 — 3,753 (30 ) 4,699 Goodwill — 1,607 — 38,923 — 40,530 Other intangible assets, net — 39 — 28,062 — 28,101 Long-term tax assets — 643 — 559 (428 ) 774 Investment in subsidiaries 70,255 42,311 64,335 — (176,901 ) — Intercompany loans receivable 3,000 6,516 10,000 10,218 (29,734 ) — Other assets — 678 — 1,059 — 1,737 Total assets $ 73,781 $ 201,277 $ 74,505 $ 261,690 $ (504,568 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,110 $ — $ 1,324 $ — $ 2,434 Accounts payable — 261 — 1,349 — 1,610 Intercompany payable 20,506 135,091 — 141,714 (297,311 ) — Accrued compensation 1 490 — 1,120 — 1,611 Accrued income taxes 41 371 — 523 — 935 Deferred tax liabilities 3 — — 280 (164 ) 119 Other accrued expenses — 600 — 1,894 (30 ) 2,464 Total current liabilities 20,551 137,923 — 148,204 (297,505 ) 9,173 Long-term debt — 29,004 — 4,748 — 33,752 Long-term accrued compensation and retirement benefits — 965 — 570 — 1,535 Long-term accrued income taxes — 1,450 — 1,026 — 2,476 Long-term intercompany loans payable — 10,218 10,000 9,516 (29,734 ) — Long-term deferred tax liabilities — — — 5,128 (428 ) 4,700 Other long-term liabilities — 207 — 1,612 — 1,819 Total liabilities 20,551 179,767 10,000 170,804 (327,667 ) 53,455 Shareholders’ equity 53,230 21,510 64,505 90,886 (176,901 ) 53,230 Total liabilities and shareholders’ equity $ 73,781 $ 201,277 $ 74,505 $ 261,690 $ (504,568 ) $ 106,685 Condensed Consolidating Balance Sheet October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 1 $ 140 $ 1 $ 2,236 $ — $ 2,378 Investments — — — 14,851 — 14,851 Accounts receivable, net — — — 5,044 — 5,044 Inventories — — — 3,516 — 3,516 Intercompany receivable 234 — 60 20,521 (20,815 ) — Tax assets — — — 1,619 — 1,619 Prepaid expenses and other current assets 2 — 5 1,308 — 1,315 Total current assets 237 140 66 49,095 (20,815 ) 28,723 Property, plant, and equipment, net — — — 4,678 — 4,678 Goodwill — — — 41,274 — 41,274 Other intangible assets, net — — — 27,731 — 27,731 Long-term tax assets — — — 825 — 825 Investment in subsidiaries 71,544 8,794 65,524 — (145,862 ) — Intercompany loans receivable 3,000 9,175 11,827 6,421 (30,423 ) — Other assets — — — 1,714 — 1,714 Total assets $ 74,781 $ 18,109 $ 77,417 $ 131,738 $ (197,100 ) $ 104,945 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ — $ 1,307 $ 851 $ — $ 2,158 Accounts payable — — — 1,447 — 1,447 Intercompany payable 20,502 — 288 25 (20,815 ) — Accrued compensation 11 — — 1,378 — 1,389 Accrued income taxes 13 — 1 519 — 533 Deferred tax liabilities — — — 142 — 142 Other accrued expenses 1 32 — 2,424 — 2,457 Total current liabilities 20,527 32 1,596 6,786 (20,815 ) 8,126 Long-term debt — 4,539 — 29,151 — 33,690 Long-term accrued compensation and retirement benefits — — — 1,577 — 1,577 Long-term accrued income taxes — — — 2,771 — 2,771 Long-term intercompany loans payable 1,985 7,918 10,000 10,520 (30,423 ) — Long-term deferred tax liabilities — — — 4,766 — 4,766 Other long-term liabilities — — — 1,746 — 1,746 Total liabilities 22,512 12,489 11,596 57,317 (51,238 ) 52,676 Shareholders’ equity 52,269 5,620 65,821 74,421 (145,862 ) 52,269 Total liabilities and shareholders’ equity $ 74,781 $ 18,109 $ 77,417 $ 131,738 $ (197,100 ) $ 104,945 Condensed Consolidating Balance Sheet April 24, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 728 $ 170 $ 3,682 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — — — 3,463 — 3,463 Intercompany receivable 259 — 269 20,508 (21,036 ) — Tax assets — — — 1,335 — 1,335 Prepaid expenses and other current assets 4 — 6 1,444 — 1,454 Total current assets 526 728 445 50,181 (21,036 ) 30,844 Property, plant, and equipment, net — — 1 4,728 (30 ) 4,699 Goodwill — — — 40,530 — 40,530 Other intangible assets, net — — — 28,101 — 28,101 Long-term tax assets — — — 774 — 774 Investment in subsidiaries 70,255 4,277 64,335 — (138,867 ) — Intercompany loans receivable 3,000 7,401 11,303 6,372 (28,076 ) — Other assets — — — 1,737 — 1,737 Total assets $ 73,781 $ 12,406 $ 76,084 $ 132,423 $ (188,009 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,002 $ — $ 1,432 $ — $ 2,434 Accounts payable — — 2 1,608 — 1,610 Intercompany payable 20,506 — 280 250 (21,036 ) — Accrued compensation 1 — — 1,610 — 1,611 Accrued income taxes 41 — — 894 — 935 Deferred tax liabilities 3 — — 116 — 119 Other accrued expenses — 40 1 2,453 (30 ) 2,464 Total current liabilities 20,551 1,042 283 8,363 (21,066 ) 9,173 Long-term debt — 4,580 — 29,172 — 33,752 Long-term accrued compensation and retirement benefits — — — 1,535 — 1,535 Long-term accrued income taxes — — — 2,476 — 2,476 Long-term intercompany loans payable — 8,385 10,002 9,689 (28,076 ) — Long-term deferred tax liabilities — — — 4,700 — 4,700 Other long-term liabilities — — — 1,819 — 1,819 Total liabilities 20,551 14,007 10,285 57,754 (49,142 ) 53,455 Shareholders’ equity 53,230 (1,601 ) 65,799 74,669 (138,867 ) 53,230 Total liabilities and shareholders’ equity $ 73,781 $ 12,406 $ 76,084 $ 132,423 $ (188,009 ) $ 106,685
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Six Months Ended October 30, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (24 ) $ 454 $ (1,116 ) $ 2,781 $ — $ 2,095 Investing Activities: Acquisitions, net of cash acquired — — — (997 ) — (997 ) Additions to property, plant, and equipment — (129 ) — (317 ) — (446 ) Purchases of marketable securities — — — (3,370 ) — (3,370 ) Sales and maturities of marketable securities — — — 2,752 — 2,752 Net increase (decrease) in intercompany loans — (562 ) (330 ) (1,657 ) 2,549 — Other investing activities, net — — — (13 ) — (13 ) Net cash provided by (used in) investing activities — (691 ) (330 ) (3,602 ) 2,549 (2,074 ) Financing Activities: Acquisition-related contingent consideration — — — (19 ) — (19 ) Change in short-term borrowings, net — — 1,277 — — 1,277 Proceeds from short-term borrowings (maturities greater than 90 days) — 48 — — — 48 Payments on long-term debt — (600 ) — (1,008 ) — (1,608 ) Dividends to shareholders (1,075 ) — — — — (1,075 ) Issuance of ordinary shares 263 — — — — 263 Repurchase of ordinary shares (1,460 ) — — — — (1,460 ) Net intercompany loan borrowings (repayments) 1,985 3 — 561 (2,549 ) — Other financing activities 49 — — — — 49 Net cash provided by (used in) financing activities (238 ) (549 ) 1,277 (466 ) (2,549 ) (2,525 ) Effect of exchange rate changes on cash and cash equivalents — — — 39 — 39 Net change in cash and cash equivalents (262 ) (786 ) (169 ) (1,248 ) — (2,465 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ 1 $ 285 $ 1 $ 2,091 $ — $ 2,378 Condensed Consolidating Statement of Cash Flows Six Months Ended October 24, 2014 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by operating activities $ — $ 45 $ — $ 1,178 $ — $ 1,223 Investing Activities: Acquisitions, net of cash acquired — — — (578 ) — (578 ) Additions to property, plant, and equipment — (78 ) — (132 ) — (210 ) Purchases of marketable securities — — — (3,024 ) — (3,024 ) Sales and maturities of marketable securities — — — 2,665 — 2,665 Net decrease in intercompany loans — — — 23 (23 ) — Other investing activities, net — — — (6 ) — (6 ) Net cash used in investing activities — (78 ) — (1,052 ) (23 ) (1,153 ) Financing Activities: Acquisition-related contingent consideration — — — (5 ) — (5 ) Change in short-term borrowings, net — 1,611 — — — 1,611 Proceeds from short-term borrowings (maturities greater than 90 days) — 150 — — — 150 Payments on long-term debt — (7 ) — — — (7 ) Dividends to shareholders — (602 ) — — — (602 ) Issuance of ordinary shares — 312 — — — 312 Repurchase of ordinary shares — (1,620 ) — — — (1,620 ) Net intercompany loan borrowings (repayments) — (23 ) — — 23 — Other financing activities — 34 — — — 34 Net cash (used in) provided by financing activities — (145 ) — (5 ) 23 (127 ) Effect of exchange rate changes on cash and cash equivalents — — — (59 ) — (59 ) Net change in cash and cash equivalents — (178 ) — 62 — (116 ) Cash and cash equivalents at beginning of period — 264 — 1,139 — 1,403 Cash and cash equivalents at end of period $ — $ 86 $ — $ 1,201 $ — $ 1,287 Condensed Consolidating Statement of Cash Flows Six Months Ended October 30, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (24 ) $ 2,605 $ (920 ) $ 2,984 $ (2,550 ) $ 2,095 Investing Activities: Acquisitions, net of cash acquired — — — (997 ) — (997 ) Additions to property, plant, and equipment — — — (446 ) — (446 ) Purchases of marketable securities — — — (3,370 ) — (3,370 ) Sales and maturities of marketable securities — — — 2,752 — 2,752 Net decrease in intercompany loans — (1,774 ) (524 ) (49 ) 2,347 — Other investing activities, net — — — (13 ) — (13 ) Net cash provided by (used in) investing activities — (1,774 ) (524 ) (2,123 ) 2,347 (2,074 ) Financing Activities: Acquisition-related contingent consideration — — — (19 ) — (19 ) Change in short-term borrowings, net — — 1,277 — — 1,277 Proceeds from short-term borrowings (maturities greater than 90 days) — 48 — — — 48 Payments on long-term debt — (1,000 ) — (608 ) — (1,608 ) Dividends to shareholders (1,075 ) — — — — (1,075 ) Issuance of ordinary shares 263 — — — — 263 Repurchase of ordinary shares (1,460 ) — — — — (1,460 ) Net intercompany loan borrowings (repayments) 1,985 (467 ) (2 ) 831 (2,347 ) — Intercompany dividend paid — — — (2,550 ) 2,550 — Other financing activities 49 — — — — 49 Net cash provided by (used in) financing activities (238 ) (1,419 ) 1,275 (2,346 ) 203 (2,525 ) Effect of exchange rate changes on cash and cash equivalents — — — 39 — 39 Net change in cash and cash equivalents (262 ) (588 ) (169 ) (1,446 ) — (2,465 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ 1 $ 140 $ 1 $ 2,236 $ — $ 2,378

Basis of Presentation (Details)

Basis of Presentation (Details)	6 Months Ended
	Oct. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year 2016 duration	371 days

Acquisitions and Acquisition-41

Acquisitions and Acquisition-Related Items - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 30, 2015	Oct. 02, 2015	Aug. 31, 2015	Aug. 11, 2015	Apr. 24, 2015	Jan. 26, 2015
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 41,274				$ 40,530
Covidien plc [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable						$ 1,349
Inventories						2,221
Other current assets						3,134
Property, plant, and equipment						2,333
Goodwill						29,608
Intangible assets						26,194
Other assets						771
Total assets acquired						65,610
Short-term borrowings						1,011
Other current liabilities						2,418
Long-term debt						4,623
Long-term deferred tax liabilities						4,809
Other long-term liabilities						2,761
Total liabilities assumed						15,622
Net assets acquired						49,988
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Accounts receivable	0
Inventories	(1)
Other current assets	185
Property, plant, and equipment	(21)
Goodwill	22
Intangible assets	(71)
Other assets	24
Total assets acquired	138
Short-term borrowings	0
Other current liabilities	87
Long-term debt	0
Long-term deferred tax liabilities	73
Other long-term liabilities	(22)
Total liabilities assumed	138
Net assets acquired	0
Covidien plc [Member] | Scenario, Previously Reported [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable						1,349
Inventories						2,222
Other current assets						2,949
Property, plant, and equipment						2,354
Goodwill						29,586
Intangible assets						26,265
Other assets						747
Total assets acquired						65,472
Short-term borrowings						1,011
Other current liabilities						2,331
Long-term debt						4,623
Long-term deferred tax liabilities						4,736
Other long-term liabilities						2,783
Total liabilities assumed						15,484
Net assets acquired						$ 49,988
Acquisitions 2016 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	147
Property, plant, and equipment	7
IPR&D	422
Other intangible assets	235
Goodwill	729
Other assets	8
Total assets acquired	1,548
Current liabilities	88
Long-term deferred tax liabilities	134
Other long-term liabilities	2
Total liabilities assumed	224
Net assets acquired	1,324
Twelve, Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets		$ 60
Property, plant, and equipment		0
IPR&D		192
Other intangible assets		0
Goodwill		301
Other assets		0
Total assets acquired		553
Current liabilities		37
Long-term deferred tax liabilities		44
Other long-term liabilities		0
Total liabilities assumed		81
Net assets acquired		$ 472
RF Surgical Systems, Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets				$ 43
Property, plant, and equipment				3
IPR&D				0
Other intangible assets				115
Goodwill				132
Other assets				2
Total assets acquired				295
Current liabilities				28
Long-term deferred tax liabilities				27
Other long-term liabilities				0
Total liabilities assumed				55
Net assets acquired				$ 240
Medina Medical [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets			$ 11
Property, plant, and equipment			0
IPR&D			122
Other intangible assets			0
Goodwill			126
Other assets			0
Total assets acquired			259
Current liabilities			6
Long-term deferred tax liabilities			34
Other long-term liabilities			0
Total liabilities assumed			40
Net assets acquired			$ 219
All Other 2016 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	33
Property, plant, and equipment	4
IPR&D	108
Other intangible assets	120
Goodwill	170
Other assets	6
Total assets acquired	441
Current liabilities	17
Long-term deferred tax liabilities	29
Other long-term liabilities	2
Total liabilities assumed	48
Net assets acquired	$ 393
Acquisitions 2015 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets					70
Property, plant, and equipment					18
IPR&D					71
Other intangible assets					316
Goodwill					473
Other assets					55
Total assets acquired					1,003
Current liabilities					44
Long-term deferred tax liabilities					117
Other long-term liabilities					4
Total liabilities assumed					165
Net assets acquired					838
NGC Medical S.p.A. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets					55
Property, plant, and equipment					15
IPR&D					0
Other intangible assets					159
Goodwill					197
Other assets					3
Total assets acquired					429
Current liabilities					34
Long-term deferred tax liabilities					51
Other long-term liabilities					4
Total liabilities assumed					89
Net assets acquired					340
Sapiens Steering Brain Stimulation [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets					3
Property, plant, and equipment					1
IPR&D					30
Other intangible assets					0
Goodwill					170
Other assets					3
Total assets acquired					207
Current liabilities					4
Long-term deferred tax liabilities					0
Other long-term liabilities					0
Total liabilities assumed					4
Net assets acquired					203
All Other 2015 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets					12
Property, plant, and equipment					2
IPR&D					41
Other intangible assets					157
Goodwill					106
Other assets					49
Total assets acquired					367
Current liabilities					6
Long-term deferred tax liabilities					66
Other long-term liabilities					0
Total liabilities assumed					72
Net assets acquired					$ 295

Acquisitions and Acquisition-42

Acquisitions and Acquisition-Related Items - Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	$ 291	$ 87	$ 264	$ 68
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning Balance	291	87	264	68
Purchase price contingent consideration	109	0	135	23
Contingent consideration payments	(17)	0	(20)	(5)
Change in fair value of contingent consideration	(15)	4	(11)	5
Ending Balance	368	$ 91	368	$ 91
Revenue-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	203		203
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Ending Balance	203		$ 203
Revenue-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			11.00%
Probability of payment			30.00%
Revenue-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			27.20%
Probability of payment			100.00%
Product development-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	165		$ 165
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Ending Balance	$ 165		$ 165
Product development-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			0.60%
Probability of payment			15.00%
Product development-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			5.50%
Probability of payment			100.00%

Acquisitions and Acquisition-43

Acquisitions and Acquisition-Related Items - Narrative (Details) $ / shares in Units, $ in Millions

Oct. 02, 2015USD ($)

Aug. 31, 2015USD ($)

Aug. 11, 2015USD ($)

Jan. 26, 2015USD ($)$ / shares

Oct. 30, 2015USD ($)

Oct. 24, 2014USD ($)

Oct. 30, 2015USD ($)

Oct. 24, 2014USD ($)

Jul. 31, 2015USD ($)

Apr. 24, 2015USD ($)

Jan. 23, 2015

Jul. 25, 2014USD ($)

Apr. 25, 2014USD ($)

Business Acquisition [Line Items]

Goodwill

$ 41,274

$ 41,274

$ 40,530

Acquisition-related items

49

$ 61

120

$ 102

Fair value of contingent consideration

368

$ 91

368

$ 91

$ 291

264

$ 87

$ 68

Other long-term liabilities [Member]

Business Acquisition [Line Items]

Fair value of contingent consideration

313

313

242

Other accrued expenses [Member]

Business Acquisition [Line Items]

Fair value of contingent consideration

55

55

$ 22

Covidien plc [Member]

Business Acquisition [Line Items]

Cash consideration per Covidien share (usd per share) | $ / shares

$ 35.19

Consideration - number of shares issued for each Covidien share, conversion ratio

0.956

Consideration - total

$ 50,000

Consideration - cash

16,000

Consideration - non-cash

34,000

Percentage ownership by Medtronic shareholders subsequent to acquisition

69.00%

Percentage ownership by Covidien shareholders subsequent to acquisition

31.00%

Goodwill

29,608

Opening balance sheet adjustment - assets

138

Contingent liabilities assumed

2,200

Covidien plc [Member] | Contingent Liability, Income Tax [Member]

Business Acquisition [Line Items]

Contingent liabilities assumed

1,500

Covidien plc [Member] | Contingent Liability, Legal [Member]

Business Acquisition [Line Items]

Contingent liabilities assumed

500

Covidien plc [Member] | Contingent liability, Environmental Matters [Member]

Business Acquisition [Line Items]

Contingent liabilities assumed

200

Covidien plc [Member] | Pelvic mesh [Member]

Business Acquisition [Line Items]

Opening balance sheet adjustment - assets

121

Covidien plc [Member] | IPR&D [Member]

Business Acquisition [Line Items]

IPR&D

400

Covidien plc [Member] | Customer-related [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 18,300

Finite-lived intangible assets, useful life

18 years

Covidien plc [Member] | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 7,000

Finite-lived intangible assets, useful life

16 years

Covidien plc [Member] | Tradenames [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 400

Finite-lived intangible assets, useful life

6 years

Twelve, Inc. [Member]

Business Acquisition [Line Items]

Consideration - total

$ 472

Consideration - cash

428

Finite-lived intangible assets

0

IPR&D

192

Goodwill

301

Contingent consideration

$ 44

RF Surgical Systems, Inc. [Member]

Business Acquisition [Line Items]

Consideration - total

$ 240

Finite-lived intangible assets

115

IPR&D

0

Goodwill

132

RF Surgical Systems, Inc. [Member] | Customer-related [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 47

Finite-lived intangible assets, useful life

15 years

RF Surgical Systems, Inc. [Member] | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 68

Finite-lived intangible assets, useful life

18 years

Medina Medical [Member]

Business Acquisition [Line Items]

Consideration - total

$ 195

Consideration - cash

155

Finite-lived intangible assets

0

IPR&D

122

Goodwill

126

Contingent consideration

64

Consideration - total, including equity interest in acquiree held prior to combination

$ 219

Equity interest in acquiree held prior to acquisition

11.00%

Business combinations or purchases of intellectual property prior to April 24, 2009 [Member]

Business Acquisition [Line Items]

Maximum amount of future contingent consideration payments

$ 191

$ 191

Special Charges and Certain L44

Special Charges and Certain Litigation Charges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Loss Contingencies [Line Items]
Special gains (charges)	$ 0	$ 100	$ 0	$ 100
Certain litigation charges	26	$ 0	26	$ 0
INFUSE [Member] | Product liability litigation [Member]
Loss Contingencies [Line Items]
Certain litigation charges	$ 26		$ 26

Restructuring Charges, Net - Re

Restructuring Charges, Net - Restructuring Reserve (Details) - USD ($) $ in Millions	Jan. 26, 2015	Oct. 30, 2015	Jul. 31, 2015	Apr. 24, 2015
Cost Synergies Initiative [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		$ 127	$ 143
Restructuring charges		86	67	$ 248
Payments/write-downs		(44)	(83)
Reversal of excess accrual		(13)
Ending balance		156	127	143
Cost Synergies Initiative [Member] | Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		112	136
Restructuring charges		64	52	213
Payments/write-downs		(28)	(76)
Reversal of excess accrual		(13)
Ending balance		135	112	136
Cost Synergies Initiative [Member] | Asset Write-downs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		0	0
Restructuring charges		10	0	28
Payments/write-downs		(10)	0
Reversal of excess accrual		0
Ending balance		0	0	0
Cost Synergies Initiative [Member] | Other Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		15	7
Restructuring charges		12	15	1
Payments/write-downs		(6)	(7)
Reversal of excess accrual		0
Ending balance		21	15	7
Covidien Initiative [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		60	78
Payments/write-downs		(14)	(18)
Reversal of excess accrual				(5)
Ending balance	$ 103	46	60	78
Covidien Initiative [Member] | Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		48	61
Restructuring charges	76
Payments/write-downs		(8)	(13)
Ending balance		40	48	61
Covidien Initiative [Member] | Other Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		12	17
Restructuring charges	$ 27
Payments/write-downs		(6)	(5)
Ending balance		$ 6	$ 12	$ 17

Restructuring Charges, Net - Na

Restructuring Charges, Net - Narrative (Details) - USD ($) $ in Millions	Jan. 26, 2015	Oct. 30, 2015	Jul. 31, 2015	Apr. 24, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Cost Synergies Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 86	$ 67	$ 248
Reversal of excess accrual		13
Impairment of property, plant and equipment		10			$ 0	$ 10	$ 9
Restructuring reserve		156	127	143		156
Cost Synergies Initiative [Member] | Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		64	52	213
Reversal of excess accrual		13
Restructuring reserve		135	112	136		135
Cost Synergies Initiative [Member] | Asset write-downs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		10	0	28
Reversal of excess accrual		0
Restructuring reserve		0	0	0		0
Cost Synergies Initiative [Member] | Inventory write-offs [Member] | Cost of products sold [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				15
Cost Synergies Initiative [Member] | Contract termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				6
Cost Synergies Initiative [Member] | Other costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		12	15	1
Reversal of excess accrual		0
Restructuring reserve		21	15	7		21
Cost Synergies Initiative [Member] | Covidien plc [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost synergies	$ 850
Covidien Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual				5
Restructuring reserve	103	46	60	78		46
Covidien Initiative [Member] | Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	76
Restructuring reserve		40	48	61		40
Covidien Initiative [Member] | Other costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 27
Restructuring reserve		$ 6	$ 12	$ 17		$ 6

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Presentation, and AFS in Continuous Loss Position (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Available-for-sale securities:
Cost	$ 15,276	$ 14,734
Unrealized Gains	105	205
Unrealized Losses	(409)	(193)
Fair Value	14,972	14,746
Trading securities:
Cost	65	58
Unrealized Gains	16	19
Unrealized Losses	0	0
Fair Value	81	77
Cost method, equity method, and other investments:
Cost	484	520
Total investments [Abstract]
Cost	15,825	15,312
Unrealized Gains	121	224
Unrealized Losses	(409)	(193)
Fair Value	15,053	14,823
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	5,916	2,941
Less than 12 months, Unrealized Losses	(161)	(141)
More than 12 months, Fair Value	1,780	1,171
More than 12 months, Unrealized Losses	(248)	(52)
Investments [Member]
Available-for-sale securities:
Fair Value	14,770	14,560
Trading securities:
Fair Value	81	77
Cost method, equity method, and other investments:
Cost	0	0
Total investments [Abstract]
Fair Value	14,851	14,637
Other Assets [Member]
Available-for-sale securities:
Fair Value	202	186
Trading securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	484	520
Total investments [Abstract]
Fair Value	686	706
Level 1 [Member]
Available-for-sale securities:
Cost	1,775	1,589
Unrealized Gains	30	52
Unrealized Losses	(7)	(20)
Fair Value	1,798	1,621
Trading securities:
Cost	65	58
Unrealized Gains	16	19
Unrealized Losses	0	0
Fair Value	81	77
Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,699	1,541
Trading securities:
Fair Value	81	77
Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	99	80
Trading securities:
Fair Value	0	0
Level 2 [Member]
Available-for-sale securities:
Cost	13,391	13,035
Unrealized Gains	75	153
Unrealized Losses	(395)	(169)
Fair Value	13,071	13,019
Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	13,071	13,019
Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Level 3 [Member]
Available-for-sale securities:
Cost	110	110
Unrealized Gains	0	0
Unrealized Losses	(7)	(4)
Fair Value	103	106
Cost method, equity method, and other investments:
Cost	484	520
Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	0	0
Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	103	106
Cost method, equity method, and other investments:
Cost	484	520
Corporate debt securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	2,932	944
Less than 12 months, Unrealized Losses	(50)	(9)
More than 12 months, Fair Value	183	34
More than 12 months, Unrealized Losses	(6)	(1)
Corporate debt securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	6,618	6,282
Unrealized Gains	50	105
Unrealized Losses	(56)	(10)
Fair Value	6,612	6,377
Corporate debt securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	6,612	6,377
Corporate debt securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	1	1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1	1
Corporate debt securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	1	1
U.S. government and agency securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,146	356
Less than 12 months, Unrealized Losses	(5)	(1)
More than 12 months, Fair Value	142	267
More than 12 months, Unrealized Losses	(2)	(3)
U.S. government and agency securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	1,696	1,525
Unrealized Gains	7	17
Unrealized Losses	(4)	(1)
Fair Value	1,699	1,541
U.S. government and agency securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,699	1,541
U.S. government and agency securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
U.S. government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	1,537	1,597
Unrealized Gains	3	4
Unrealized Losses	(3)	(3)
Fair Value	1,537	1,598
U.S. government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,537	1,598
U.S. government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	26	4
Less than 12 months, Unrealized Losses	(3)	(19)
More than 12 months, Fair Value	0	0
More than 12 months, Unrealized Losses	0	0
Marketable equity securities [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	99	80
Marketable equity securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	79	64
Unrealized Gains	23	35
Unrealized Losses	(3)	(19)
Fair Value	99	80
Marketable equity securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	99	80
Mortgage-backed securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	622	346
Less than 12 months, Unrealized Losses	(10)	(3)
More than 12 months, Fair Value	225	206
More than 12 months, Unrealized Losses	(4)	(3)
Mortgage-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	1,466	1,462
Unrealized Gains	14	22
Unrealized Losses	(14)	(6)
Fair Value	1,466	1,478
Mortgage-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,466	1,478
Mortgage-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Foreign government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	65	85
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	65	85
Foreign government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	65	85
Foreign government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Certificates of deposit [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	47	44
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	47	44
Certificates of deposit [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	47	44
Certificates of deposit [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Other asset-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	510	504
Unrealized Gains	2	3
Unrealized Losses	0	0
Fair Value	512	507
Other asset-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	512	507
Other asset-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Debt funds [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,190	1,291
Less than 12 months, Unrealized Losses	(93)	(109)
More than 12 months, Fair Value	1,128	559
More than 12 months, Unrealized Losses	(229)	(41)
Debt funds [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	3,148	3,061
Unrealized Gains	6	19
Unrealized Losses	(322)	(150)
Fair Value	2,832	2,930
Debt funds [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	2,832	2,930
Debt funds [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	102	105
More than 12 months, Unrealized Losses	(7)	(4)
Auction rate securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	109	109
Unrealized Gains	0	0
Unrealized Losses	(7)	(4)
Fair Value	102	105
Auction rate securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	102	105
Exchange-traded funds [Member] | Level 1 [Member]
Trading securities:
Cost	65	58
Unrealized Gains	16	19
Unrealized Losses	0	0
Fair Value	81	77
Exchange-traded funds [Member] | Level 1 [Member] | Investments [Member]
Trading securities:
Fair Value	81	77
Exchange-traded funds [Member] | Level 1 [Member] | Other Assets [Member]
Trading securities:
Fair Value	$ 0	$ 0

Financial Instruments - Unobser

Financial Instruments - Unobservable Inputs, and Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3) (Details) - Recurring [Member] - Level 3 [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 103	$ 108	$ 106	$ 106
Total unrealized gains (losses) included in other comprehensive income	0	0	(3)	2
Ending balance	103	108	103	108
Corporate debt securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1	9	1	9
Total unrealized gains (losses) included in other comprehensive income	0	0	0	0
Ending balance	1	9	1	9
Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	102	99	105	97
Total unrealized gains (losses) included in other comprehensive income	0	0	(3)	2
Ending balance	$ 102	$ 99	$ 102	$ 99
Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			3 years
Illiquidity premium			6.00%
Minimum [Member] | Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			2 years
Maximum [Member] | Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			12 years

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
AFS Debt Maturities
Due in one year or less	$ 2,245		$ 2,245
Due after one year through five years	6,314		6,314
Due after five years through ten years	3,197		3,197
Due after ten years	285		285
Total	12,041		12,041
Debt [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	1,481	$ 806	2,718	$ 2,636
Gross realized gains	4	4	9	16
Gross realized losses	(7)	(2)	(12)	(5)
Impairment losses recognized	0	0	0	0
Equity [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	5	7	34	29
Gross realized gains	20	39	32	58
Gross realized losses	0	0	0	0
Impairment losses recognized	(19)	(20)	(42)	(20)
Equity [Member] | Other expense, net [Member]
AFS Gross Realized Gain (Loss)
Gross realized gains	$ 9	$ 35	$ 9	$ 41

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014	Apr. 24, 2015
Schedule of Investments [Line Items]
Marketable securities	$ 14,972		$ 14,972		$ 14,746
Cost	484		484		520
Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment, cost method investments	19	$ 13	21	$ 13
Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	202		202		186
Cost	484		484		520
Debt securities [Member]
Schedule of Investments [Line Items]
Credit loss portion of other-than-temporary impairments	0		0		0
Reductions for available-for-sale securities sold	0	0	0	0
Other-than-temporary impairment losses on available-for-sale securities	0	0	0	0
Marketable equity securities [Member] | Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment charges, marketable securities	0	$ 7	20	$ 7
Marketable equity securities [Member] | Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	$ 99		$ 99		$ 80

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 30, 2015	Apr. 24, 2015
Debt Instrument [Line Items]
Deferred gains from interest rate swap terminations, net	$ 0	$ 3
Debt premium	440	499
Total Long-Term Debt	$ 33,690	33,752
Senior notes [Member] | Floating rate three-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Term of debt instrument	3 years
Long-term Debt	$ 250	250
Senior notes [Member] | 0.875 percent three-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	0.875%
Term of debt instrument	3 years
Long-term Debt	$ 250	250
Senior notes [Member] | 6.000 percent ten-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.00%
Term of debt instrument	10 years
Long-term Debt	$ 1,150	1,150
Senior notes [Member] | 1.500 percent three-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.50%
Term of debt instrument	3 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 1.375 percent five-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.375%
Term of debt instrument	5 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 5.600 percent ten-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.60%
Term of debt instrument	10 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.450 percent ten-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.45%
Term of debt instrument	10 years
Long-term Debt	$ 1,250	1,250
Senior notes [Member] | 4.200 percent ten-year 2010 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.20%
Term of debt instrument	10 years
Long-term Debt	$ 600	600
Senior notes [Member] | 2.500 percent five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.50%
Term of debt instrument	5 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | Floating rate five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Term of debt instrument	5 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.125 percent ten-year 2011 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term Debt	$ 500	500
Senior notes [Member] | 3.125 percent ten-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term Debt	$ 675	675
Senior notes [Member] | 3.200 percent ten-year 2012 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term Debt	$ 650	650
Senior notes [Member] | 3.150 percent seven-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | 2.750 percent ten-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term Debt	$ 1,250	1,250
Senior notes [Member] | 2.950 percent ten-year 2013 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term Debt	$ 750	750
Senior notes [Member] | 3.625 percent ten-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term Debt	$ 850	850
Senior notes [Member] | 3.500 percent ten-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | 4.375 percent twenty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | 6.550 percent thirty-year 2007 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term Debt	$ 850	850
Senior notes [Member] | 6.500 percent thirty-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term Debt	$ 300	300
Senior notes [Member] | 5.550 percent thirty-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.500 percent thirty-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.000 percent thirty-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term Debt	$ 750	750
Senior notes [Member] | 4.625 percent thirty-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 650	650
Senior notes [Member] | 4.625 percent thirty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | Three-year term loan [Member]
Debt Instrument [Line Items]
Term of debt instrument	3 years
Long-term Debt	$ 3,000	3,000
Interest rate swaps [Member]
Debt Instrument [Line Items]
Long-term Debt	72	79
Capital lease obligations [Member]
Debt Instrument [Line Items]
Capital lease obligations	121	129
Bank borrowings [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 32	$ 17

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Oct. 30, 2015	Oct. 30, 2015	Apr. 24, 2015
Debt Instrument, Fair Value Disclosure [Abstract]
Long-term debt (including short-term portion), fair value	$ 31,913,000,000	$ 31,913,000,000	$ 34,637,000,000
Long-term debt (including short-term portion), principal value	30,525,000,000	30,525,000,000	32,125,000,000
2015 Commercial Paper Program [Member] | Commercial Paper [Member]
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount	3,500,000,000	$ 3,500,000,000
Commercial paper, maximum maturities		364 days
Commercial paper, amount outstanding	$ 1,307,000,000	$ 1,307,000,000	0
Weighted average original maturity	47 days	45 days
Weighted average interest rate	0.44%	0.42%
Amended and Restated Revolving Credit Agreement [Member] | Line of Credit [Member]
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000	$ 3,500,000,000
Term of debt instrument		5 years
Line of credit, amount outstanding	$ 0	$ 0	$ 0

Derivatives and Foreign Excha53

Derivatives and Foreign Exchange Risk Management - Gains (Losses) on Derivatives and Amounts Reclassified into Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Other expense, net [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency exchange rate contracts gains (losses)	$ (4)	$ 73	$ 16	$ 49
Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative	17	229	3	291
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	74	21	148	19
Cash flow hedging [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative	17	229	3	291
Cash flow hedging [Member] | Other expense, net [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	89	20	184	21
Cash flow hedging [Member] | Cost of products sold [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	$ (15)	$ 1	$ (36)	$ (2)

Derivatives and Foreign Excha54

Derivatives and Foreign Exchange Risk Management - Location and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 498	$ 733
Liability Derivatives, Fair Value	132	116
Interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	74	89
Liability Derivatives, Fair Value	72	71
Foreign currency exchange rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	403	644
Liability Derivatives, Fair Value	47	45
Commodity derivatives [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	9
Cross currency interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	21
Liability Derivatives, Fair Value	4
Designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	449	614
Liability Derivatives, Fair Value	95	86
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	2	10
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	72	79
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0	0
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other long-term liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	72	71
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	286	382
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	89	143
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	18	12
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other long-term liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	5	3
Not designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	49	119
Liability Derivatives, Fair Value	37	30
Not designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	28	119
Not designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	24	$ 30
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	0
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	9
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	21
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other long-term liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 4

Derivatives and Foreign Excha55

Derivatives and Foreign Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets	$ 403	$ 644
Derivative Liabilities	47	45
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets	95	89
Derivative Liabilities	85	71
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets	0	0
Derivative Liabilities	$ 0	$ 0

Derivatives and Foreign Excha56

Derivatives and Foreign Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	$ 498	$ 733
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(74)	(71)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(217)	(338)
Derivative Assets, Net Amount	207	324
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(132)	(116)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	74	71
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	16	8
Derivative Liabilities, Net Amount	(42)	(37)
Gross Amount of Recognized Assets (Liabilities)	366	617
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(201)	(330)
Net Amount	165	287
Foreign currency exchange rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	403	644
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(66)	(61)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(205)	(325)
Derivative Assets, Net Amount	132	258
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(47)	(45)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	39	31
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(8)	(14)
Interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	74	89
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(8)	(10)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(12)	(13)
Derivative Assets, Net Amount	54	66
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(72)	(71)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	35	40
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	16	8
Derivative Liabilities, Net Amount	(21)	$ (23)
Cross currency interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	21
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Assets, Net Amount	21
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(4)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Liabilities, Net Amount	(4)
Commodity derivatives [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(9)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Liabilities, Net Amount	$ (9)

Derivatives and Foreign Excha57

Derivatives and Foreign Exchange Risk Management - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014	Apr. 24, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Currency exchange rate gains (losses)	$ 55,000,000	$ 14,000,000	$ 98,000,000	$ 2,000,000
Gains (losses) relating to ineffectiveness of foreign currency cash flow hedges	0	0	0	0
Gain (losses) relating to ineffectiveness of forward starting interest rate derivatives	0	0	0	0
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	154,000,000		154,000,000		$ 210,000,000
Cash flow hedge unrealized gains to be reclassified over the next 12 months			166,000,000
Gains (losses) relating to ineffectiveness of interest rate fair value hedges	0	0	0	0
Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	74,000,000	21,000,000	148,000,000	19,000,000
Foreign currency exchange rate contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	10,086,000,000		10,086,000,000		9,782,000,000
Foreign currency exchange rate contracts [Member] | Not designated as hedging instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	3,653,000,000		3,653,000,000		4,713,000,000
Foreign currency exchange rate contracts [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 6,433,000,000		6,433,000,000		5,069,000,000
Maximum remaining maturity of foreign currency derivatives	3 years
Interest rate swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Unrealized gains (losses) on outstanding forward starting interest rate swap derivative instruments	$ (27,000,000)		(27,000,000)		(71,000,000)
Interest rate swaps [Member] | Cash flow hedging [Member] | Interest expense, net [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	(3,000,000)	$ (2,000,000)	(6,000,000)	$ (4,000,000)
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	300,000,000		$ 300,000,000
Notional amount of derivatives terminated	500,000,000
Payment for derivatives terminated	$ 45,000,000
Weighted average fixed rate of interest rate derivatives	3.10%		3.10%
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Fair Value Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 1,425,000,000		$ 1,425,000,000		$ 2,025,000,000
Market value of outstanding interest rate swap agreements - net unrealized gain	47,000,000		47,000,000
Market value of hedged item - net unrealized loss	$ 47,000,000		$ 47,000,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 2,244	$ 2,268
Work in-process	527	509
Raw materials	745	686
Total	$ 3,516	$ 3,463

Goodwill and Other Intangible59

Goodwill and Other Intangible Assets, Net - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	6 Months Ended
	Oct. 30, 2015USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 40,530
Goodwill as a result of acquisitions	732
Purchase accounting adjustments, net	20
Currency adjustment, net	(8)
Ending balance	41,274
Cardiac and Vascular Group [Member]
Goodwill [Roll Forward]
Beginning balance	5,855
Goodwill as a result of acquisitions	409
Purchase accounting adjustments, net	24
Currency adjustment, net	(6)
Ending balance	6,282
Minimally Invasive Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	23,399
Goodwill as a result of acquisitions	132
Purchase accounting adjustments, net	(9)
Currency adjustment, net	0
Ending balance	23,522
Restorative Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	9,424
Goodwill as a result of acquisitions	191
Purchase accounting adjustments, net	5
Currency adjustment, net	(3)
Ending balance	9,617
Diabetes Group [Member]
Goodwill [Roll Forward]
Beginning balance	1,852
Goodwill as a result of acquisitions	0
Purchase accounting adjustments, net	0
Currency adjustment, net	1
Ending balance	$ 1,853

Goodwill and Other Intangible60

Goodwill and Other Intangible Assets, Net - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	$ 769	$ 720
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	30,778	30,329
Accumulated Amortization	(3,816)	(2,948)
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	769	470
Tradenames [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	0	250
Customer-related [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	18,579	18,492
Accumulated Amortization	(801)	(273)
Purchased technology and patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	11,265	11,118
Accumulated Amortization	(2,560)	(2,268)
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	850	640
Accumulated Amortization	(408)	(363)
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	84	79
Accumulated Amortization	$ (47)	$ (44)

Goodwill and Other Intangible61

Goodwill and Other Intangible Assets, Net - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Oct. 30, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2,016	$ 964
2,017	1,913
2,018	1,882
2,019	1,789
2,020	1,741
2,021	$ 1,724

Goodwill and Other Intangible62

Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014	Apr. 24, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Purchase accounting adjustments, net			$ 20,000,000
Amortization expense	$ 483,000,000	$ 89,000,000	964,000,000	$ 176,000,000
Carrying amount of goodwill	41,274,000,000		41,274,000,000		$ 40,530,000,000
Goodwill impairment	0	0	0	0
Carrying amount of amortizable intangible assets	26,962,000,000		26,962,000,000		27,381,000,000
Impairment of amortizable intangible assets	0	0	0	0
Indefinite-lived Intangible Assets [Line Items]
Carrying amount of non-amortizable intangible assets	769,000,000		769,000,000		720,000,000
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Carrying amount of non-amortizable intangible assets	769,000,000		769,000,000		$ 470,000,000
Impairment of non-amortizable intangible assets	$ 0	$ 0	$ 0	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014	Apr. 24, 2015
Income Tax Disclosure [Abstract]
Tax charge, primarily associated with internal reorganization of certain businesses	$ 442
Effective tax rate from continuing operations	52.00%	19.00%	33.80%	19.30%
Gross unrecognized tax benefits	$ 2,602		$ 2,602		$ 2,860
Accrued income tax interest and penalties	588		588
Unrecognized tax benefits that would impact effective tax rate	2,022		2,022
Gross unrecognized tax benefits, current liability	5		5
Gross unrecognized tax benefits, long-term liability	$ 2,597		$ 2,597

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Numerator:
Net income attributable to ordinary shareholders	$ 520	$ 828	$ 1,340	$ 1,699
Denominator:
Basic weighted average shares outstanding (shares)	1,412.9	981.9	1,415.6	987.5
Effect of dilutive securities:
Employee stock options (shares)	12.2	7.3	12.7	7.4
Employee restricted stock units (shares)	3.6	3.7	4.3	4.4
Other (shares)	0.1	0.1	0.1	0.1
Diluted weighted average shares outstanding (shares)	1,428.8	993	1,432.7	999.4
Basic earnings per share (usd per share)	$ 0.37	$ 0.84	$ 0.95	$ 1.72
Diluted earnings per share (usd per share)	$ 0.36	$ 0.83	$ 0.94	$ 1.70
Stock options and restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	22		21
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	6	4	3	2
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)		1		1

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 113	$ 48	$ 209	$ 82
Income tax benefits	(34)	(14)	(63)	(23)
Total stock-based compensation expense, net of tax	79	34	146	59
Cost of products sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	14	4	26	8
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	9	20	15
Selling, general and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	65	35	114	59
Restructuring charges, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6	0	14	0
Acquisition-related items [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	16	0	35	0
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	62	14	119	20
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	46	31	80	54
Employee stock purchase plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5	$ 3	$ 10	$ 8

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	$ 30	$ 26	$ 60	$ 52
Interest cost	31	26	62	52
Expected return on plan assets	(45)	(39)	(90)	(78)
Amortization of net actuarial loss	24	16	48	32
Net periodic benefit cost	40	29	80	58
Non-U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	22	15	44	30
Interest cost	9	8	18	16
Expected return on plan assets	(13)	(10)	(26)	(20)
Amortization of net actuarial loss	6	3	12	6
Net periodic benefit cost	$ 24	$ 16	$ 48	$ 32

Accumulated Other Comprehensi67

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			$ (1,184)	$ (597)
Other comprehensive (loss) income before reclassifications, before tax			(322)	211
Tax benefit (expense)			91	(115)
Other comprehensive (loss) income before reclassifications, net of tax			(231)	96
Reclassifications, before tax			(93)	(6)
Tax benefit (expense)			37	1
Reclassifications, net of tax			(56)	(5)
Other comprehensive (loss) income	$ (115)	$ (18)	(287)	91
Ending balance	(1,471)	(506)	(1,471)	(506)
Unrealized Gain (Loss) on Available-for-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			14	(6)
Other comprehensive (loss) income before reclassifications, before tax			(302)	61
Tax benefit (expense)			108	(22)
Other comprehensive (loss) income before reclassifications, net of tax			(194)	39
Reclassifications, before tax			(20)	(28)
Tax benefit (expense)			7	9
Reclassifications, net of tax			(13)	(19)
Other comprehensive (loss) income			(207)	20
Ending balance	(193)	14	(193)	14
Cumulative Translation Adjustments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(277)	218
Other comprehensive (loss) income before reclassifications, before tax			(59)	(129)
Tax benefit (expense)			0	0
Other comprehensive (loss) income before reclassifications, net of tax			(59)	(129)
Reclassifications, before tax			0	0
Tax benefit (expense)			0	0
Reclassifications, net of tax			0	0
Other comprehensive (loss) income			(59)	(129)
Ending balance	(336)	89	(336)	89
Net Change in Retirement Obligations [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(1,131)	(765)
Other comprehensive (loss) income before reclassifications, before tax			(5)	16
Tax benefit (expense)			0	0
Other comprehensive (loss) income before reclassifications, net of tax			(5)	16
Reclassifications, before tax			60	38
Tax benefit (expense)			(20)	(12)
Reclassifications, net of tax			40	26
Other comprehensive (loss) income			35	42
Ending balance	(1,096)	(723)	(1,096)	(723)
Unrealized Gain (Loss) on Derivatives [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			210	(44)
Other comprehensive (loss) income before reclassifications, before tax			44	263
Tax benefit (expense)			(17)	(93)
Other comprehensive (loss) income before reclassifications, net of tax			27	170
Reclassifications, before tax			(133)	(16)
Tax benefit (expense)			50	4
Reclassifications, net of tax			(83)	(12)
Other comprehensive (loss) income			(56)	158
Ending balance	$ 154	$ 114	$ 154	$ 114

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions

Dec. 01, 2015claim

Aug. 07, 2015patent

Dec. 04, 2014USD ($)

Jan. 22, 2014patent

Jun. 20, 2013USD ($)

May. 01, 2013USD ($)

Mar. 28, 2013USD ($)

Aug. 19, 2010landfill

Jun. 29, 2007

Jul. 31, 2015USD ($)

Oct. 30, 2015USD ($)claim

Oct. 24, 2014USD ($)

Oct. 30, 2015USD ($)claim

Oct. 24, 2014USD ($)

Apr. 24, 2015USD ($)

Jan. 26, 2015USD ($)

Jul. 25, 2014USD ($)

Apr. 25, 2014USD ($)

Apr. 26, 2013USD ($)

Apr. 07, 2009USD ($)milestone_payment

Loss Contingencies [Line Items]

Accrued certain litigation charges

$ 777

$ 777

$ 879

Certain litigation charges

26

$ 0

26

$ 0

Total contingent milestone payments

$ 291

$ 368

$ 91

368

$ 91

$ 264

$ 87

$ 68

Covidien plc [Member]

Loss Contingencies [Line Items]

Tax sharing percentage, parent

42.00%

Tax sharing percentage, former parent

27.00%

Tax sharing percentage, former affiliate

31.00%

Internal Revenue Service (IRS) [Member]

Loss Contingencies [Line Items]

Estimate of additional taxes owed

$ 914

Estimate of additional penalties owed

154

Internal Revenue Service (IRS) [Member] | Tax Year 1997 Through Tax Year 2000 [Member]

Loss Contingencies [Line Items]

Disallowed deductions

3,000

Internal Revenue Service (IRS) [Member] | Tax Years Subsequent to 2000 [Member]

Loss Contingencies [Line Items]

Disallowed deductions

$ 6,600

Indemnification Agreement [Member] | Tax Years Prior To 2013 [Member] | Covidien plc [Member]

Loss Contingencies [Line Items]

Maximum potential loss for tax indemnification

$ 200

Orrington, Maine Chemical Manufacturing Facility [Member]

Loss Contingencies [Line Items]

Number of landfills requiring removal | landfill

2

Number of landfills requiring capping | landfill

3

Penobscot River and Bay Remediation [Member]

Loss Contingencies [Line Items]

Low cost estimate for potential remediation

25

High cost estimate for potential remediation

$ 235

INFUSE [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims | claim

6,000

6,000

Certain litigation charges

$ 26

$ 26

INFUSE [Member] | Subsequent Event [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of claims settled | claim

3,900

Pelvic mesh [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims | claim

11,500

11,500

Settlement receivable

$ 121

Pelvic mesh [Member] | Subsequent Event [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of claims settled | claim

4,200

Ethicon patent infringement [Member]

Loss Contingencies [Line Items]

Patents found not infringed | patent

4

7

Patents found invalid | patent

5

Ethicon patent infringement [Member] | Positive Outcome of Litigation [Member]

Loss Contingencies [Line Items]

Damages awarded - gain (reversal of gain)

$ (177)

$ 177

Acquisition Agreement with Appriva Medical, Inc. [Member] | Breach of Contract [Member]

Loss Contingencies [Line Items]

Number of contingent milestone payments | milestone_payment

4

Total contingent milestone payments

$ 175

Damages awarded - loss

$ 175

Acquisition Agreement with Appriva Medical, Inc. [Member] | Breach of Contract [Member] | Covidien plc [Member]

Loss Contingencies [Line Items]

Accrued certain litigation charges

$ 35

Settlement of preacquisition contingency

$ 65

$ 65

Segment and Geographic Inform69

Segment and Geographic Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Segment Reporting Information [Line Items]
Net sales	$ 7,058	$ 4,366	$ 14,332	$ 8,639
Income before Income Taxes by Reportable Segment
Special charges	0	(100)	0	(100)
Restructuring charges, net	(73)	0	(140)	(30)
Certain litigation charges	(26)	0	(26)	0
Acquisition-related items	(49)	(61)	(120)	(102)
Interest expense, net	(217)	(8)	(408)	(13)
Income from operations before income taxes	1,083	1,022	2,023	2,105
Americas [Member]
Segment Reporting Information [Line Items]
Net sales	4,390	2,643	8,835	5,133
U.S. [Member]
Segment Reporting Information [Line Items]
Net sales	4,098	2,456	8,240	4,789
EMEA [Member]
Segment Reporting Information [Line Items]
Net sales	1,567	1,069	3,236	2,202
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net sales	736	433	1,506	866
Greater China [Member]
Segment Reporting Information [Line Items]
Net sales	365	221	755	438
Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,708	1,257	3,458	2,499
Segment Reconciling Items [Member]
Income before Income Taxes by Reportable Segment
Special charges	0	(100)	0	(100)
Impact of inventory step-up	0	0	(226)	0
Restructuring charges, net	(73)	0	(140)	(30)
Certain litigation charges	(26)	0	(26)	0
Acquisition-related items	(49)	(61)	(120)	(102)
Interest expense, net	(217)	(8)	(408)	(13)
Corporate, Non-Segment [Member]
Income before Income Taxes by Reportable Segment
Corporate	(260)	(66)	(515)	(149)
Cardiac and Vascular Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,482	2,286	5,050	4,540
Cardiac and Vascular Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	755	714	1,572	1,426
Minimally Invasive Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,356	0	4,812	0
Minimally Invasive Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	348	0	682	0
Restorative Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	1,770	1,650	3,576	3,253
Restorative Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	483	426	964	836
Diabetes Group [Member]
Segment Reporting Information [Line Items]
Net sales	450	430	894	846
Diabetes Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	$ 122	$ 117	$ 240	$ 237

Guarantor Financial Informati70

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014	Oct. 30, 2015	Oct. 24, 2014
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,058	$ 4,366	$ 14,332	$ 8,639
Costs and expenses:
Cost of products sold	2,182	1,142	4,638	2,247
Research and development expense	545	374	1,103	739
Selling, general, and administrative expense	2,343	1,507	4,792	3,013
Special (gains) charges, net	0	100	0	100
Restructuring charges, net	73	0	140	30
Certain litigation charges	26	0	26	0
Acquisition-related items	49	61	120	102
Amortization of intangible assets	483	89	964	176
Other (income) expense, net	57	63	118	114
Operating profit	1,300	1,030	2,431	2,118
Interest income	(107)	(86)	(222)	(178)
Interest expense	324	94	630	191
Interest expense, net	217	8	408	13
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	1,083	1,022	2,023	2,105
Provision (benefit) for income taxes	563	194	683	406
Net income	520	828	1,340	1,699
Other comprehensive income (loss), net of tax	(115)	(18)	(287)	91
Comprehensive income	405	810	1,053	1,790
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	(363)	(318)	(739)	(616)
Costs and expenses:
Cost of products sold	(556)	(320)	(666)	(616)
Research and development expense	20	0	20	0
Selling, general, and administrative expense	(46)	0	(46)	0
Special (gains) charges, net		0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other (income) expense, net	0	0	0	0
Operating profit	219	2	(47)	0
Interest income	241	0	486	0
Interest expense	(241)	0	(486)	0
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	(4,894)	1,033	(2,262)	2,053
Income from operations before income taxes	5,113	(1,031)	2,215	(2,053)
Provision (benefit) for income taxes	0	0	0	0
Net income	5,113	(1,031)	2,215	(2,053)
Other comprehensive income (loss), net of tax	362	23	878	(86)
Comprehensive income	5,475	(1,008)	3,093	(2,139)
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	26		26
Research and development expense	20		20
Selling, general, and administrative expense	(46)		(46)
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	0		0
Operating profit	0		0
Interest income	333		676
Interest expense	(333)		(676)
Interest expense, net	0		0
Equity in net (income) loss of subsidiaries	8,300		9,947
Income from operations before income taxes	(8,300)		(9,947)
Provision (benefit) for income taxes	0		0
Net income	(8,300)		(9,947)
Other comprehensive income (loss), net of tax	121		637
Comprehensive income	(8,179)		(9,310)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	54	0	149	0
Special (gains) charges, net		0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other (income) expense, net	56	0	34	0
Operating profit	(110)	0	(183)	0
Interest income	0	0	0	0
Interest expense	4	0	5	0
Interest expense, net	4	0	5	0
Equity in net (income) loss of subsidiaries	(590)	0	(1,520)	0
Income from operations before income taxes	476	0	1,332	0
Provision (benefit) for income taxes	(2)	0	(8)	0
Net income	478	0	1,340	0
Other comprehensive income (loss), net of tax	(115)	0	(287)	0
Comprehensive income	363	0	1,053	0
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	54		149
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	56		34
Operating profit	(110)		(183)
Interest income	0		0
Interest expense	4		5
Interest expense, net	4		5
Equity in net (income) loss of subsidiaries	(590)		(1,520)
Income from operations before income taxes	476		1,332
Provision (benefit) for income taxes	(2)		(8)
Net income	478		1,340
Other comprehensive income (loss), net of tax	(115)		(287)
Comprehensive income	363		1,053
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	363	309	736	612
Costs and expenses:
Cost of products sold	345	304	700	602
Research and development expense	85	118	219	234
Selling, general, and administrative expense	42	242	224	483
Special (gains) charges, net		100		100
Restructuring charges, net	5	6	5	6
Certain litigation charges	0		0
Acquisition-related items	55	98	55	98
Amortization of intangible assets	3	3	6	6
Other (income) expense, net	(348)	(318)	(579)	(533)
Operating profit	176	(244)	106	(384)
Interest income	(57)	0	(121)	0
Interest expense	455	84	899	173
Interest expense, net	398	84	778	173
Equity in net (income) loss of subsidiaries	5,902	(1,033)	4,947	(2,053)
Income from operations before income taxes	(6,124)	705	(5,619)	1,496
Provision (benefit) for income taxes	3	(121)	(159)	(203)
Net income	(6,127)	826	(5,460)	1,699
Other comprehensive income (loss), net of tax	(52)	(18)	(224)	91
Comprehensive income	(6,179)	808	(5,684)	1,790
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	1		1
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	0		0
Operating profit	(1)		(1)
Interest income	(150)		(310)
Interest expense	27		59
Interest expense, net	(123)		(251)
Equity in net (income) loss of subsidiaries	(7,292)		(7,262)
Income from operations before income taxes	7,414		7,512
Provision (benefit) for income taxes	0		0
Net income	7,414		7,512
Other comprehensive income (loss), net of tax	109		(63)
Comprehensive income	7,523		7,449
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special (gains) charges, net		0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other (income) expense, net	0	0	0	0
Operating profit	0	0	0	0
Interest income	(175)	0	(358)	0
Interest expense	3	0	3	0
Interest expense, net	(172)	0	(355)	0
Equity in net (income) loss of subsidiaries	(418)	0	(1,165)	0
Income from operations before income taxes	590	0	1,520	0
Provision (benefit) for income taxes	0	0	0	0
Net income	590	0	1,520	0
Other comprehensive income (loss), net of tax	(115)	0	(287)	0
Comprehensive income	475	0	1,233	0
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	0		0
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	0		0
Operating profit	0		0
Interest income	(175)		(358)
Interest expense	3		3
Interest expense, net	(172)		(355)
Equity in net (income) loss of subsidiaries	(418)		(1,165)
Income from operations before income taxes	590		1,520
Provision (benefit) for income taxes	0		0
Net income	590		1,520
Other comprehensive income (loss), net of tax	(115)		(287)
Comprehensive income	475		1,233
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	7,058	4,375	14,335	8,643
Costs and expenses:
Cost of products sold	2,393	1,158	4,604	2,261
Research and development expense	440	256	864	505
Selling, general, and administrative expense	2,293	1,265	4,465	2,530
Special (gains) charges, net		0		0
Restructuring charges, net	68	(6)	135	24
Certain litigation charges	26		26
Acquisition-related items	(6)	(37)	65	4
Amortization of intangible assets	480	86	958	170
Other (income) expense, net	349	381	663	647
Operating profit	1,015	1,272	2,555	2,502
Interest income	(116)	(86)	(229)	(178)
Interest expense	103	10	209	18
Interest expense, net	(13)	(76)	(20)	(160)
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	1,028	1,348	2,575	2,662
Provision (benefit) for income taxes	562	315	850	609
Net income	466	1,033	1,725	2,053
Other comprehensive income (loss), net of tax	(195)	(23)	(367)	86
Comprehensive income	271	$ 1,010	1,358	$ 2,139
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	7,058		14,332
Costs and expenses:
Cost of products sold	2,156		4,612
Research and development expense	525		1,083
Selling, general, and administrative expense	2,334		4,688
Restructuring charges, net	73		140
Certain litigation charges	26		26
Acquisition-related items	49		120
Amortization of intangible assets	483		964
Other (income) expense, net	1		84
Operating profit	1,411		2,615
Interest income	(115)		(230)
Interest expense	623		1,239
Interest expense, net	508		1,009
Equity in net (income) loss of subsidiaries	0		0
Income from operations before income taxes	903		1,606
Provision (benefit) for income taxes	565		691
Net income	338		915
Other comprehensive income (loss), net of tax	(115)		(287)
Comprehensive income	$ 223		$ 628

Guarantor Financial Informati71

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015	Oct. 24, 2014	Apr. 25, 2014
Current assets:
Cash and cash equivalents	$ 2,378	$ 4,843	$ 1,287	$ 1,403
Investments	14,851	14,637
Accounts receivable, net	5,044	5,112
Inventories	3,516	3,463
Intercompany receivable	0	0
Tax assets	1,619	1,335
Prepaid expenses and other current assets	1,315	1,454
Total current assets	28,723	30,844
Property, plant, and equipment, net	4,678	4,699
Goodwill	41,274	40,530
Other intangible assets, net	27,731	28,101
Long-term tax assets	825	774
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,714	1,737
Total assets	104,945	106,685
Current liabilities:
Short-term borrowings	2,158	2,434
Accounts payable	1,447	1,610
Intercompany payable	0	0
Accrued compensation	1,389	1,611
Accrued income taxes	533	935
Deferred tax liabilities	142	119
Other accrued expenses	2,457	2,464
Total current liabilities	8,126	9,173
Long-term debt	33,690	33,752
Long-term accrued compensation and retirement benefits	1,577	1,535
Long-term accrued income taxes	2,771	2,476
Long-term intercompany loans payable	0	0
Long-term deferred tax liabilities	4,766	4,700
Other long-term liabilities	1,746	1,819
Total liabilities	52,676	53,455
Shareholders’ equity	52,269	53,230
Total liabilities and shareholders’ equity	104,945	106,685
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	(234)	0
Intercompany receivable	(327,327)	(297,311)
Tax assets	0	(164)
Prepaid expenses and other current assets	0	0
Total current assets	(327,561)	(297,475)
Property, plant, and equipment, net	0	(30)
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	(428)
Investment in subsidiaries	(174,289)	(176,901)
Intercompany loans receivable	(32,283)	(29,734)
Other assets	0	0
Total assets	(534,133)	(504,568)
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	(327,327)	(297,311)
Accrued compensation	0	0
Accrued income taxes	0	0
Deferred tax liabilities	0	(164)
Other accrued expenses	0	(30)
Total current liabilities	(327,327)	(297,505)
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	(32,283)	(29,734)
Long-term deferred tax liabilities	0	(428)
Other long-term liabilities	0	0
Total liabilities	(359,610)	(327,667)
Shareholders’ equity	(174,523)	(176,901)
Total liabilities and shareholders’ equity	(534,133)	(504,568)
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	(20,815)	(21,036)
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(20,815)	(21,036)
Property, plant, and equipment, net	0	(30)
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	(145,862)	(138,867)
Intercompany loans receivable	(30,423)	(28,076)
Other assets	0	0
Total assets	(197,100)	(188,009)
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	(20,815)	(21,036)
Accrued compensation	0	0
Accrued income taxes	0	0
Deferred tax liabilities	0	0
Other accrued expenses	0	(30)
Total current liabilities	(20,815)	(21,066)
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	(30,423)	(28,076)
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	(51,238)	(49,142)
Shareholders’ equity	(145,862)	(138,867)
Total liabilities and shareholders’ equity	(197,100)	(188,009)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	1	263	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	234	259
Tax assets	0	0
Prepaid expenses and other current assets	2	4
Total current assets	237	526
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	71,544	70,255
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	74,781	73,781
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	20,502	20,506
Accrued compensation	11	1
Accrued income taxes	13	41
Deferred tax liabilities	0	3
Other accrued expenses	1	0
Total current liabilities	20,527	20,551
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	1,985	0
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	22,512	20,551
Shareholders’ equity	52,269	53,230
Total liabilities and shareholders’ equity	74,781	73,781
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	1	263
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	234	259
Tax assets	0	0
Prepaid expenses and other current assets	2	4
Total current assets	237	526
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	71,544	70,255
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	74,781	73,781
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	20,502	20,506
Accrued compensation	11	1
Accrued income taxes	13	41
Deferred tax liabilities	0	3
Other accrued expenses	1	0
Total current liabilities	20,527	20,551
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	1,985	0
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	22,512	20,551
Shareholders’ equity	52,269	53,230
Total liabilities and shareholders’ equity	74,781	73,781
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	285	1,071	86	264
Investments	14	0
Accounts receivable, net	0	0
Inventories	170	165
Intercompany receivable	162,699	146,373
Tax assets	376	770
Prepaid expenses and other current assets	115	128
Total current assets	163,659	148,507
Property, plant, and equipment, net	1,026	976
Goodwill	1,672	1,607
Other intangible assets, net	36	39
Long-term tax assets	535	643
Investment in subsidiaries	37,221	42,311
Intercompany loans receivable	7,078	6,516
Other assets	697	678
Total assets	211,924	201,277
Current liabilities:
Short-term borrowings	501	1,110
Accounts payable	233	261
Intercompany payable	151,757	135,091
Accrued compensation	461	490
Accrued income taxes	0	371
Deferred tax liabilities	0	0
Other accrued expenses	503	600
Total current liabilities	153,455	137,923
Long-term debt	29,000	29,004
Long-term accrued compensation and retirement benefits	996	965
Long-term accrued income taxes	1,159	1,450
Long-term intercompany loans payable	10,221	10,218
Long-term deferred tax liabilities	0	0
Other long-term liabilities	234	207
Total liabilities	195,065	179,767
Shareholders’ equity	16,859	21,510
Total liabilities and shareholders’ equity	211,924	201,277
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	140	728
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	140	728
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	8,794	4,277
Intercompany loans receivable	9,175	7,401
Other assets	0	0
Total assets	18,109	12,406
Current liabilities:
Short-term borrowings	0	1,002
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Deferred tax liabilities	0	0
Other accrued expenses	32	40
Total current liabilities	32	1,042
Long-term debt	4,539	4,580
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	7,918	8,385
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	12,489	14,007
Shareholders’ equity	5,620	(1,601)
Total liabilities and shareholders’ equity	18,109	12,406
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	1	170	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	1	170
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	65,524	64,335
Intercompany loans receivable	10,330	10,000
Other assets	0	0
Total assets	75,855	74,505
Current liabilities:
Short-term borrowings	1,307	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	1	0
Deferred tax liabilities	0	0
Other accrued expenses	0	0
Total current liabilities	1,308	0
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	10,000	10,000
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	11,308	10,000
Shareholders’ equity	64,547	64,505
Total liabilities and shareholders’ equity	75,855	74,505
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	1	170
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	60	269
Tax assets	0	0
Prepaid expenses and other current assets	5	6
Total current assets	66	445
Property, plant, and equipment, net	0	1
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	65,524	64,335
Intercompany loans receivable	11,827	11,303
Other assets	0	0
Total assets	77,417	76,084
Current liabilities:
Short-term borrowings	1,307	0
Accounts payable	0	2
Intercompany payable	288	280
Accrued compensation	0	0
Accrued income taxes	1	0
Deferred tax liabilities	0	0
Other accrued expenses	0	1
Total current liabilities	1,596	283
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	10,000	10,002
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	11,596	10,285
Shareholders’ equity	65,821	65,799
Total liabilities and shareholders’ equity	77,417	76,084
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	2,091	3,339	$ 1,201	$ 1,139
Investments	14,837	14,637
Accounts receivable, net	5,044	5,112
Inventories	3,580	3,298
Intercompany receivable	164,394	150,679
Tax assets	1,243	729
Prepaid expenses and other current assets	1,198	1,322
Total current assets	192,387	179,116
Property, plant, and equipment, net	3,652	3,753
Goodwill	39,602	38,923
Other intangible assets, net	27,695	28,062
Long-term tax assets	290	559
Investment in subsidiaries	0	0
Intercompany loans receivable	11,875	10,218
Other assets	1,017	1,059
Total assets	276,518	261,690
Current liabilities:
Short-term borrowings	350	1,324
Accounts payable	1,214	1,349
Intercompany payable	155,068	141,714
Accrued compensation	917	1,120
Accrued income taxes	519	523
Deferred tax liabilities	142	280
Other accrued expenses	1,953	1,894
Total current liabilities	160,163	148,204
Long-term debt	4,690	4,748
Long-term accrued compensation and retirement benefits	581	570
Long-term accrued income taxes	1,612	1,026
Long-term intercompany loans payable	10,077	9,516
Long-term deferred tax liabilities	4,766	5,128
Other long-term liabilities	1,512	1,612
Total liabilities	183,401	170,804
Shareholders’ equity	93,117	90,886
Total liabilities and shareholders’ equity	276,518	261,690
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	2,236	3,682
Investments	14,851	14,637
Accounts receivable, net	5,044	5,112
Inventories	3,516	3,463
Intercompany receivable	20,521	20,508
Tax assets	1,619	1,335
Prepaid expenses and other current assets	1,308	1,444
Total current assets	49,095	50,181
Property, plant, and equipment, net	4,678	4,728
Goodwill	41,274	40,530
Other intangible assets, net	27,731	28,101
Long-term tax assets	825	774
Investment in subsidiaries	0	0
Intercompany loans receivable	6,421	6,372
Other assets	1,714	1,737
Total assets	131,738	132,423
Current liabilities:
Short-term borrowings	851	1,432
Accounts payable	1,447	1,608
Intercompany payable	25	250
Accrued compensation	1,378	1,610
Accrued income taxes	519	894
Deferred tax liabilities	142	116
Other accrued expenses	2,424	2,453
Total current liabilities	6,786	8,363
Long-term debt	29,151	29,172
Long-term accrued compensation and retirement benefits	1,577	1,535
Long-term accrued income taxes	2,771	2,476
Long-term intercompany loans payable	10,520	9,689
Long-term deferred tax liabilities	4,766	4,700
Other long-term liabilities	1,746	1,819
Total liabilities	57,317	57,754
Shareholders’ equity	74,421	74,669
Total liabilities and shareholders’ equity	$ 131,738	$ 132,423

Guarantor Financial Informati72

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 30, 2015	Oct. 24, 2014
Operating Activities:
Net cash provided by (used in) operating activities	$ 2,095	$ 1,223
Investing Activities:
Acquisitions, net of cash acquired	(997)	(578)
Additions to property, plant, and equipment	(446)	(210)
Purchases of marketable securities	(3,370)	(3,024)
Sales and maturities of marketable securities	2,752	2,665
Net increase (decrease) in intercompany loans	0	0
Other investing activities, net	(13)	(6)
Net cash used in investing activities	(2,074)	(1,153)
Financing Activities:
Acquisition-related contingent consideration	(19)	(5)
Change in short-term borrowings, net	1,277	1,611
Proceeds from short-term borrowings (maturities greater than 90 days)	48	150
Payments on long-term debt	(1,608)	(7)
Dividends to shareholders	(1,075)	(602)
Issuance of ordinary shares	263	312
Repurchase of ordinary shares	(1,460)	(1,620)
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	0
Other financing activities, net	49	34
Net cash used in financing activities	(2,525)	(127)
Effect of exchange rate changes on cash and cash equivalents	39	(59)
Net change in cash and cash equivalents	(2,465)	(116)
Cash and cash equivalents at beginning of period	4,843	1,403
Cash and cash equivalents at end of period	2,378	1,287
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	2,549	(23)
Other investing activities, net	0	0
Net cash used in investing activities	2,549	(23)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(2,549)	23
Other financing activities, net	0	0
Net cash used in financing activities	(2,549)	23
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(2,550)
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	2,347
Other investing activities, net	0
Net cash used in investing activities	2,347
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	0
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	(2,347)
Intercompany dividend paid	2,550
Other financing activities, net	0
Net cash used in financing activities	203
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	0
Cash and cash equivalents at beginning of period	0
Cash and cash equivalents at end of period	0
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(24)	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	0	0
Other investing activities, net	0	0
Net cash used in investing activities	0	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,075)	0
Issuance of ordinary shares	263	0
Repurchase of ordinary shares	(1,460)	0
Net intercompany loan borrowings (repayments)	1,985	0
Other financing activities, net	49	0
Net cash used in financing activities	(238)	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(262)	0
Cash and cash equivalents at beginning of period	263	0
Cash and cash equivalents at end of period	1	0
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(24)
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	0
Other investing activities, net	0
Net cash used in investing activities	0
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	0
Dividends to shareholders	(1,075)
Issuance of ordinary shares	263
Repurchase of ordinary shares	(1,460)
Net intercompany loan borrowings (repayments)	1,985
Intercompany dividend paid	0
Other financing activities, net	49
Net cash used in financing activities	(238)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(262)
Cash and cash equivalents at beginning of period	263
Cash and cash equivalents at end of period	1
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	454	45
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	(129)	(78)
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	(562)	0
Other investing activities, net	0	0
Net cash used in investing activities	(691)	(78)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	0	1,611
Proceeds from short-term borrowings (maturities greater than 90 days)	48	150
Payments on long-term debt	(600)	(7)
Dividends to shareholders	0	(602)
Issuance of ordinary shares	0	312
Repurchase of ordinary shares	0	(1,620)
Net intercompany loan borrowings (repayments)	3	(23)
Other financing activities, net	0	34
Net cash used in financing activities	(549)	(145)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(786)	(178)
Cash and cash equivalents at beginning of period	1,071	264
Cash and cash equivalents at end of period	285	86
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	2,605
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	(1,774)
Other investing activities, net	0
Net cash used in investing activities	(1,774)
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	0
Proceeds from short-term borrowings (maturities greater than 90 days)	48
Payments on long-term debt	(1,000)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	(467)
Intercompany dividend paid	0
Other financing activities, net	0
Net cash used in financing activities	(1,419)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(588)
Cash and cash equivalents at beginning of period	728
Cash and cash equivalents at end of period	140
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(1,116)	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	(330)	0
Other investing activities, net	0	0
Net cash used in investing activities	(330)	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	1,277	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Other financing activities, net	0	0
Net cash used in financing activities	1,277	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(169)	0
Cash and cash equivalents at beginning of period	170	0
Cash and cash equivalents at end of period	1	0
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(920)
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	(524)
Other investing activities, net	0
Net cash used in investing activities	(524)
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	1,277
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	0
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	(2)
Intercompany dividend paid	0
Other financing activities, net	0
Net cash used in financing activities	1,275
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(169)
Cash and cash equivalents at beginning of period	170
Cash and cash equivalents at end of period	1
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	2,781	1,178
Investing Activities:
Acquisitions, net of cash acquired	(997)	(578)
Additions to property, plant, and equipment	(317)	(132)
Purchases of marketable securities	(3,370)	(3,024)
Sales and maturities of marketable securities	2,752	2,665
Net increase (decrease) in intercompany loans	(1,657)	23
Other investing activities, net	(13)	(6)
Net cash used in investing activities	(3,602)	(1,052)
Financing Activities:
Acquisition-related contingent consideration	(19)	(5)
Change in short-term borrowings, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Payments on long-term debt	(1,008)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	561	0
Other financing activities, net	0	0
Net cash used in financing activities	(466)	(5)
Effect of exchange rate changes on cash and cash equivalents	39	(59)
Net change in cash and cash equivalents	(1,248)	62
Cash and cash equivalents at beginning of period	3,339	1,139
Cash and cash equivalents at end of period	2,091	$ 1,201
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	2,984
Investing Activities:
Acquisitions, net of cash acquired	(997)
Additions to property, plant, and equipment	(446)
Purchases of marketable securities	(3,370)
Sales and maturities of marketable securities	2,752
Net increase (decrease) in intercompany loans	(49)
Other investing activities, net	(13)
Net cash used in investing activities	(2,123)
Financing Activities:
Acquisition-related contingent consideration	(19)
Change in short-term borrowings, net	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	(608)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	831
Intercompany dividend paid	(2,550)
Other financing activities, net	0
Net cash used in financing activities	(2,346)
Effect of exchange rate changes on cash and cash equivalents	39
Net change in cash and cash equivalents	(1,446)
Cash and cash equivalents at beginning of period	3,682
Cash and cash equivalents at end of period	$ 2,236

Guarantor Financial Informati73

Guarantor Financial Information - Narrative (Details) - USD ($) $ in Millions	Oct. 30, 2015	Apr. 24, 2015
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	$ 0	$ 0
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	$ 8,794	4,277
Subsidiary Issuer [Member] | CIFSA Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries		2,763
Subsidiary Issuer [Member] | CIFSA Notes [Member] | Restatement adjustment [Member] | Internal reorganization [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries		1,093
Subsidiary Issuer [Member] | CIFSA Notes [Member] | Restatement adjustment [Member] | Intercompany dividend [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries		$ 1,670